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EXAMINING THE ROLE OF METABOLIC PATHWAYS AS THERAPEUTIC 
MODALITIES FOR TRIPLE NEGATIVE BREAST CANCER 
 
 
Triple negative breast cancer (TNBC) comprises 15-20% of breast 
cancers, affects a younger patient population than other subtypes, and is very 
aggressive. TNBC is comprised of a diverse group of tumors that have proven 
refractory to targeted therapy and can be difficult to treat. Patients generally 
receive neoadjuvant chemotherapy (NAC), surgery, and radiotherapy. The 
standard of care for NAC includes a taxane, an anthracycline, and/or 
cyclophosphamide, and administration of NAC has resulted in pathological 
complete response (pCR) in 30-40% of patients. However, a majority of TNBC 
patients will not reach pCR and instead have residual disease (RD), which is 
associated with worse outcomes. Patients with RD are more likely to experience 
locoregional or distant recurrence, and they have lower rates of overall survival, 
breast cancer-specific survival, disease-free survival, and distant relapse-free 
survival. Five-year survival rates for TNBC are 91% for localized disease, 65% 
with regional recurrence, and only 11% with distant recurrence. The reductions in 
survival with metastasis indicate that patients who have RD after receiving NAC 
desperately need novel interventions. AMP-activated protein kinase (AMPK) and 
protein kinase B (Akt) are important cellular energy regulators that have been 
implicated in cancer therapy and progression. However, further work is needed to 
fully establish their roles as therapeutic modalities in TNBC. This study analyzed 
whether targeting the AMPK and Akt signaling pathways can enhance TNBC 
therapy or reduce TNBC metastasis. 
 
  Chemical activation of AMPK suppresses growth of cancer cells, but many 
common AMPK activators—such as AICAR or 2-deoxyglucose—have low 
sensitivity and require dosing in the millimolar range. This has led to their 
unsuccessful translation to the clinic. FND-4b is a novel compound that activates 
AMPK at micromolar concentrations in colorectal cancer cells, but its effects in 
TNBC are unknown. Treatment of TNBC cells with FND-4b induced AMPK 
activation and signaling through its downstream pathways. Phosphorylation of 
 
acetyl CoA carboxylase (ACC)—a direct target of AMPK—was increased, 
indicating a decrease in fatty acid synthesis. Furthermore, activation of ribosomal 
protein S6 was reduced, which suggests reduced flux through the mTOR 
pathway. FND-4b also suppressed proliferation of TNBC in a dose-dependent 
manner in the low micromolar range, which is substantially lower than well-known 
AMPK activators. Finally, FND-4b increased apoptosis induction in TNBC cells at 
micromolar doses. Taken together, these findings indicate that FND-4b reduces 
proliferation and induces apoptosis through AMPK activation in TNBC cells at 
lower doses than many other AMPK activators. 
 
AMPK inhibition has increased sensitivity of cancer cells to radiotherapy 
due to suppression of autophagy. Chemical inhibition of the PI3K signaling 
cascade has also potentiated radiation-induced cell death in TNBC cells. 
However, the ability of individual AMPK or Akt isoforms to sensitize TNBC cells 
to radiotherapy has not been studied. Moreover, while a double-negative 
feedback loop exists between AMPK and Akt—a downstream effector of PI3K—
the impact of combined inhibition of AMPK and Akt isoforms on TNBC survival 
after radiation is unknown. Immunohistochemical (IHC) staining indicated that 
AMPKα1 is expressed in only the cytoplasm of TNBC, while AMPKα2 is found in 
both the cytoplasm and the nucleus. AMPKα1 or AMPKα2 knockdown decreased 
proliferation and induced G1 cell cycle arrest in TNBC cells but did not induce 
apoptosis alone or in combination with radiotherapy. The role of PI3K p85α, 
p85β, p110α, p110β, Akt1, and Akt2 proteins on TNBC cell cycle progression 
and apoptosis induction was then analyzed. Akt1 and p110α suppressed cyclin 
D1 expression and induced apoptosis. Silencing Akt1 potentiated radiation-
induced apoptosis and further suppressed survival of TNBC cells after radiation 
exposure. Treatment of TNBC cells with the Akt inhibitor MK-2206 48 h after 
radiotherapy decreased Akt1 expression and promoted synergistic apoptosis 
induction. Taken together, these results indicate that inhibiting Akt1 expression is 
a potentially promising approach to enhance TNBC treatment. 
 
Distant spread of TNBC is correlated with a substantial drop in 5-year 
survival. However, the ability of Akt isoforms to mediate TNBC metastasis is 
unknown, and the specific steps of metastasis that are regulated by AMPKα 
isoforms are unclear. In addition, combined inhibition of Akt and AMPKα isoforms 
to suppress TNBC metastatic spread has not been attempted. IHC staining 
indicated that Akt1, Akt2, and AMPKα1 were primarily expressed in the 
cytoplasm of TNBC lymph node metastases. IHC staining also showed that 
AMPKα2 was mostly expressed in both the cytoplasm and nucleus of TNBC 
lymph node metastases. Silencing Akt2 reduced expression of the invasive 
proteins Snail and Claudin-1 in TNBC cells. Moreover, knockdown of Akt1 and 
Akt2 induced apoptosis in TNBC cells potentially by increasing Bim expression 
and reducing Mcl-1 expression, respectively. Silencing AMPKα1 or AMPKα2 did 
not consistently affect the expression of the invasive proteins tested or induce 
apoptosis in TNBC cells. Suppressing levels of Akt1 or Akt2 significantly reduced 
TNBC lung colonization independent of Akt activity, but knocking down AMPKα1, 
 
 
 
AMPKα2, or AMPKα1/2 did not impact the ability of TNBC cells to metastasize to 
the lungs. Moreover, targeting Akt1 and AMPKα1 together did not decrease 
TNBC lung metastasis more than silencing Akt1 alone. Taken together, these 
results establish Akt1 and Akt2 as key mediators of TNBC metastasis that may 
be targeted to prevent the spread of non-responsive disease. 
 
Developing novel therapeutic strategies for TNBC patients who have RD 
after administration of NAC is vital to increasing patient survival. Improving 
current treatment regimens and reducing metastatic spread are two potential 
approaches that may prove advantageous. Pharmacological activation of AMPK 
with FND-4b suppressed TNBC growth, and future work could evaluate how 
adding AMPK activators to current NAC regimens impacts patient outcomes. 
AMPKα1 knockdown did not induce radiosensitization, but silencing Akt1 did 
potentiate radiation-induced apoptosis. Moreover, MK-2206 treatment reduced 
Akt1 expression and promoted synergistic apoptosis induction after radiotherapy. 
Further studies should determine how Akt1 suppression affects outcomes of 
TNBC patients with RD after receiving NAC. Finally, silencing Akt1 or Akt2 
dramatically decreased TNBC lung metastasis. Knockdown of AMPKα isoforms 
did not reduce TNBC lung colonization, and combined inhibition of Akt1 and 
AMPKα1 did not suppress TNBC metastasis more than targeting Akt1 alone. 
Future studies should identify pharmacological agents that can decrease 
expression of Akt1 and Akt2 and evaluate their ability to reduce metastasis. 
Taken together, these studies provide potentially promising strategies to improve 
survival among TNBC patients whose tumors are refractory to current treatment 
modalities. 
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1 
CHAPTER 1. INTRODUCTION TO TRIPLE NEGATIVE BREAST CANCER, 
AMP-ACTIVATED PROTEIN KINASE, AND PROTEIN KINASE B 
 
1.1 Triple Negative Breast Cancer is Heterogenous 
 
Breast cancer is the most common cancer in women and the second 
leading cause of cancer death among women worldwide. Estimates indicate that 
there will be more than 275,000 new cases and over 42,000 deaths among US 
women in 2020 [1]. Most deaths are due to metastatic spread to the lungs, brain, 
or bone [2]. Breast cancer is a heterogeneous disease that can be separated into 
three main types: (1) estrogen receptor-positive, (2) receptor tyrosine-protein 
kinase erbB-2 (HER2)-amplified, and (3) triple negative. Triple negative breast 
cancer (TNBC) comprises 15-20% of overall cases and is characterized by a lack 
of expression of the estrogen receptor, the progesterone receptor, and the HER2 
protein [3-7]. TNBC affects a younger patient population and has a higher 
incidence in African American women [3-5, 7-9]. It follows an aggressive clinical 
course and is associated with an increased frequency of metastatic disease [3-5]. 
Furthermore, patients with TNBC have worse prognoses than patients with other 
breast cancers [3, 4, 6, 10]. 
 
TNBC is a diagnosis of exclusion and, as such, comprises a heterogenous 
group of tumors. The most common subtype is basal-like, which describes 
tumors that express proteins found in the basal, or myoepithelial, cell layer of the 
breast [4, 11]. These include cytokeratins 5, 6, and 17 and the epidermal growth 
factor receptor [4]. Approximately 70% of basal-like breast cancers are classified 
as TNBC, while 50-75% of TNBC cases are classified as basal-like [4, 11, 12]. 
While basal-like is the most common TNBC subtype, several other classifications 
exist. Recent gene expression analysis separated TNBC into the following 
categories: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), 
mesenchymal stem cell-like (MSL), immunomodulatory (IM), and luminal 
androgen receptor-like (LAR) [3-5, 7-9, 13-16]. However, further histological 
analysis found that stromal cells or lymphocytes present in the tumors had 
influenced the classification of both the MSL and IM subtypes [11, 13, 14, 17]. 
Therefore, TNBC is now separated into BL1, BL2, M, and LAR [11, 13, 17]. The 
BL1, BL2, and M subtypes are nonluminal tumors, while LAR tumors are 
classified as luminal [11]. The BL1 subtype has high expression of genes 
involved in the DNA-damage response and control of cell cycle, while the BL2 
subtype is characterized by increased growth factor signaling and metabolic 
activity [11, 13, 18]. Both BL1 and BL2 have a high proliferative capacity and 
respond to inhibitors of mitosis, such as taxanes [11]. The M subtype contains 
high expression of genes involved in the epithelial-to-mesenchymal transition and 
genetic abnormalities in cell motility and differentiation [4, 5, 11, 18]. The LAR 
subtype expresses the androgen receptor (AR) and proteins found in luminal 
breast cancers [4, 5, 11, 16, 18, 19]. Figure 1.1 compares the frequency of the 
BL1, BL2, M, and LAR subtypes in TNBC. Further insight into TNBC 
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heterogeneity may permit the development of targeted therapies for certain 
subtypes. 
 
1.2 TNBC Treatment Strategies 
 
TNBC is more difficult to treat than estrogen receptor-positive or HER2-
amplified breast cancers. The development of targeted therapies—such as 
tamoxifen and trastuzumab—has improved the treatment of these other subtypes 
[20-23]. Tamoxifen is a selective estrogen receptor modulator and is used to treat 
tumors that grow when stimulated by estrogen [20, 21]. Trastuzumab is a 
monoclonal antibody that targets the HER2 protein, an oncogene that promotes 
cellular growth [22, 23]. By antagonizing this effect, trastuzumab has improved 
outcomes of patients whose tumors have high levels of HER2 [22, 23]. However, 
TNBC does not contain such targetable factors and has been refractory to 
targeted therapies. 
 
Efforts have been made to discover targeted therapy options in TNBC by 
focusing on p53, phosphatidylinositol-3-kinase (PI3K) signaling, BRCA1/2, and 
the AR. Mutations in the p53 gene are the most common in TNBC and comprise 
60-70% of genetic alterations [24-26]. Two compounds that can reactivate p53 
function in mutant cells—PRIMA-1 and APR-246—inhibited growth in TNBC cell 
lines [27, 28]. TNBC cells with p53 mutations were more sensitive to APR-246 
than TNBC cells with wild type p53, but further validation in vivo is still needed 
[27]. Activation of the PI3K signaling pathway is also common in TNBC, and 
phase I/II clinical trials are evaluating the use of PI3K/mTOR inhibitors in patients 
with early or advanced TNBC [9, 29]. The efficacies of two such drugs—
buparlisib and everolimus—have been evaluated in TNBC patients [9]. While the 
responses have been modest, there appears to be benefit in targeting this 
pathway in TNBC [9]. However, additional studies are needed to clearly delineate 
the effects of PI3K pathway inhibitors on patient survival. Germline mutations in 
the BRCA1/2 genes are found in 15-20% of TNBC patients and impair the ability 
for cells to fix double-stranded DNA breaks [8, 30, 31]. This deficiency in DNA 
repair has led to testing PARP inhibitors as part of TNBC therapy [5, 8, 9, 24]. 
Results so far have been mixed, but third generation derivatives—including 
veliparib and olaparib—are currently under investigation [9]. Finally, between 25-
35% of TNBC tumors express the AR, and clinical trials have indicated that 
treatment with two antiandrogens—bicalutamide and enzalutamide—have 
provided benefit in AR-expressing TNBC tumors [9]. However, more studies are 
needed to determine the minimum AR expression level for these drugs to be 
efficacious [9]. Targeting the AR is a promising therapeutic option, but 
improvements will only be realized in a subset of TNBC patients whose tumors 
depend on the AR to promote signaling and growth. 
 
Currently, the cornerstone of TNBC treatment is cytotoxic chemotherapy 
[3, 24]. TNBC tumors are more likely to respond to chemotherapy than other 
breast cancers, making this modality an attractive option [24]. Neoadjuvant 
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chemotherapy (NAC) refers to treatment that is administered before surgery and 
is becoming more prevalent among TNBC patients. The goal is to shrink the 
tumor as much as possible prior to surgery. The standard of care consists of an 
anthracycline, a taxane, and possibly a DNA alkylating agent such as 
cyclophosphamide [3, 4, 9, 17, 24]. Recently the addition of platinum-based 
compounds to the standard treatment regimen has received interest [9]. 
Platinum-induced DNA damage can lead to apoptosis in cells with a defective 
DNA damage response—particularly those with BRCA1/2 mutations [4, 24]. 
Sixty-one percent of stage I-III TNBC patients with BRCA1 mutations achieved 
pathological complete response (pCR) after neoadjuvant therapy with cisplatin 
[24]. Moreover, adding carboplatin to standard NAC significantly increased the 
rate of pCR in two separate TNBC populations [9, 24]. 
 
Localized therapies are also employed in the treatment of TNBC. After 
NAC, patients often receive surgery, radiotherapy, and possibly adjuvant 
chemotherapy [32-35]. The standard protocol for breast cancer is administration 
of 50.0 Grays (Gy) of radiation [36]. Delivery occurs in 25 sessions over 5 weeks, 
which results in 2.0 Gy being given each day [36]. There are no specific 
guidelines for radiotherapy in TNBC [8]. Recent studies have shown that 
radiation can improve TNBC patient outcomes. Radiation treatment increased 
both breast cancer-specific survival (BCSS) and overall survival (OS) among 
TNBC patients after surgery [33, 34]. The effect on BCSS was slight for patients 
in the T1-T2 population but much greater for those in the T3-T4 populations, 
suggesting that radiation benefits are greater in patients with more advanced 
tumors [34]. Radiotherapy also increased BCSS among patients who had a 
partial mastectomy but not a total mastectomy, which indicates that the type of 
surgery a patient receives may also impact the efficacy of radiotherapy [34]. 
BCSS still declines over time in patients who receive radiation, which suggests 
that there is still room for improvement [34]. 
 
1.3 Treatment Efficacy and Achieving pCR 
 
Improvements in TNBC treatment have been made, but there is still much 
work left to do. TNBC patients have a higher rate of recurrence and worse 
survival than patients with other types of breast cancer [5, 11]. Distant relapse-
free survival (DFRS) is significantly shorter among patients with TNBC than 
among those with non-TNBC [13]. In addition, TNBC survival decreases 
considerably with regional and distant metastasis. The 5-year relative survival 
rate for localized TNBC is 91% [37]. This rate drops to 65% for those with 
regional disease and plummets to 11% in cases with distant spread [37]. These 
substantial reductions in survival with metastasis underscore the importance of 
early detection and the need for effective treatments at early stages of disease. 
 
TNBC patient outcome is directly impacted by the attainment of pCR, 
which is the absence of cancer on pathological examination of the resected 
breast and all sampled lymph nodes after NAC [38]. While patients who achieve 
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pCR have better outcomes than those who do not, administration of NAC has led 
to pCR in only 30-40% of TNBC patients [24, 39-41]. This means that 60-70% of 
TNBC patients do not reach pCR and instead have residual disease (RD) at the 
time of surgical resection. Moreover, TNBC subtype impacts pCR achievement 
and subsequent clinical outcome. Compared to other TNBC patients, those with 
the BL2 subtype reach pCR at the lowest rate and have the worst median 
survival [13, 42]. One study has found that BL2 patients have a median survival 
of just 2.4 years, which is the shortest among the major TNBC subtypes [13]. 
 
TNBC patients who do not achieve pCR despite treatment with NAC 
desperately need novel interventions for two key reasons. First, those with RD 
are more likely to experience locoregional or distant recurrence than those who 
do achieve pCR [8, 43]. Patients with RD are more likely to die from distant 
spread of their cancers than those who reach pCR [13]. A recent study showed 
that TNBC patients with RD after NAC developed locoregional recurrence at a 
disproportionately higher rate than those with other breast cancers [32]. These 
patients also received surgery and radiation, which suggests that recurrent 
tumors may be resistant to localized therapies [32]. Second, disease-free 
survival, DRFS, BCSS, and OS are significantly lower in TNBC patients with RD 
than in those with pCR [13, 39-41]. A recent analysis found that 95% of TNBC 
patients with pCR were alive after 7 years while those without pCR had a median 
survival of only 2.7 years [13]. 
 
Patients with stage II or III TNBC could benefit from increasing the rate of 
pCR. Stage II disease can be classified by a tumor that is larger than 20 mm or 
the presence of 1-3 positive lymph nodes [35]. Stage III disease can be classified 
by a tumor that is larger than 50 mm or the presence of 4-9 positive lymph nodes 
[35]. Figure 1.2 outlines a standard treatment protocol for these patients, which 
includes NAC that is followed by surgery [35]. Those patients who reach pCR 
usually receive radiotherapy and are then monitored [35]. Patients who still have 
RD normally receive radiotherapy that is followed by adjuvant chemotherapy [35]. 
Capecitabine is normally administered for these patients in the adjuvant setting 
[35]. 
 
TNBC patients who are refractory to standard treatments—notably those 
with the BL2 subtype—are in dire need of novel therapeutic strategies. Two 
potential options include improving the efficacy of NAC by identifying new drug 
targets or increasing the sensitivity of cancer cells to radiotherapy. The enzymes 
AMP-activated protein kinase (AMPK) and protein kinase B (Akt) have been 
implicated in cancer therapy and progression. However, further work is needed to 
fully define their roles as therapeutic targets in TNBC. 
 
1.4 AMPK Structure and Regulation 
 
AMPK is a heterotrimer that consists of a catalytic (α) and two regulatory 
(β and γ) subunits [44-57]. Each subunit is further composed of different isoforms 
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[44-47, 50-54, 56]. The α subunit is activated via phosphorylation of Threonine 
(Thr) 172 and is responsible for phosphorylating downstream targets [44, 45, 47, 
48, 50-52, 54-57]. It contains a kinase domain (KD), an auto-inhibitory domain 
(AID), and a C-terminal domain (CTD) [47, 48]. The KD is composed of large and 
small lobes, and Thr172 is located in the large lobe [47, 48]. When associated 
with the AID, the activity of the KD is greatly reduced [47, 48]. The AID must be 
moved away from the KD to increase activation. In the active confirmation, the 
CTD protects Thr172 from dephosphorylation by phosphatases [47]. 
 
The β subunit contains a carbohydrate-binding module (CBM) and a C-
terminal domain (CTD) [47, 48]. The β-CTD links the α-CTD with the γ subunit, 
while the CBM is able to bind glycogen [47, 48]. The purpose of AMPK binding to 
glycogen is not fully understood yet [47, 48]. The γ subunit is comprised of four 
cystathione β-synthase (CBS) repeats whose main role is to detect changes in 
cellular AMP levels [47, 48, 53]. CBS1, CBS3, and CBS4 can bind to adenosine-
containing nucleotides, while CBS2 is nonfunctional and unable to do so [47, 48]. 
CBS1 is mostly bound to ATP, while CBS4 binds AMP with high affinity [58]. 
CBS3 is the only structure that has an interaction with the α subunit [58]. 
Furthermore, CBS3 can competitively bind to AMP, ADP, or ATP and is therefore 
the main sensor of variations in cellular energy [48, 53]. Binding of AMP or ADP 
to CBS3 causes the γ subunit to interact with the α subunit, which results in a 
conformational change that moves the AID away from the KD [53]. This relieves 
the inhibitory effects of the AID on the KD and ultimately leads to allosteric 
activation of AMPK [53]. 
 
AMPK is phosphorylated at Thr172 by three upstream enzymes: liver 
kinase B1 (LKB1), calcium/calmodulin dependent protein kinase kinase 2 
(CAMKK2), and transforming growth factor-β activated protein kinase-1 (TAK1) 
[44, 45, 47, 48, 50-52, 54-56]. LKB1 is a tumor suppressor that is mutated in 
Peutz-Jeghers Syndrome, a disorder in which hamartomatous polyps grow in the 
gastrointestinal tract [47, 49, 50, 55]. LKB1 exerts its anti-tumor effects by 
signaling through AMPK and twelve other related enzymes [45, 48, 55]. CAMKK2 
activates AMPK in response to increases in intracellular Ca2+ levels and works 
independently of changes in cellular AMP levels [47, 50, 52, 56]. This mechanism 
permits AMPK activation even when cells are not metabolically stressed. 
Phosphorylation of AMPK by CAMMK2 occurs in depolarized neurons in the 
hippocampus, activated T cells, and cells in which a G protein-coupled receptor 
has been stimulated to release Ca2+ intracellularly [47]. TAK1 can induce AMPK 
activation, but little is known about the physiological purpose of this signaling [48, 
56]. 
 
Changes in AMP levels are key for cells to detect and respond to energy 
stress. ATP, ADP, and AMP are related through the following reaction: 2 ADP ⇌ 
ATP + AMP [47, 48]. ATP levels are reduced during metabolic stress, causing 
the reaction to favor the production of ATP and AMP [47, 48]. Since initial AMP 
levels are much lower than initial ATP levels, changes in the AMP concentration 
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will be greater than changes in the concentration of either ATP or ADP [47]. 
Therefore, AMP levels are acute markers of metabolic stress [47]. An increase in 
AMP signifies metabolic demand and promotes AMPK activation three ways. 
First, AMP binds the γ subunit of AMPK, leading to a conformational change that 
breaks the association between the KD and the AID in the α subunit [47, 53]. 
This results in allosteric activation of AMPK [47, 53]. Next, AMP stimulates LKB1-
induced phosphorylation of Thr172 [47]. Finally, the conformational change from 
AMP binding to AMPK’s γ subunit prevents protein phosphatases from 
dephosphorylating Thr172 [47, 53]. ADP can also suppress this 
dephosphorylation, but the required concentration is 10 times higher than that for 
AMP [47]. 
 
1.5 AMPK Function 
 
1.5.1 Effects on Metabolism 
 
AMPK is activated when cellular AMP levels rise, which occurs when the 
cell is in a low energy state [47, 52]. AMPK attempts to return the cell to energy 
homeostasis by increasing ATP production and reducing ATP consumption [47, 
52]. This is accomplished through upregulation of catabolic pathways—those that 
produce ATP—and downregulation of anabolic pathways—those that consume 
ATP [47, 52, 53]. AMPK’s effects on cellular metabolism are wide-ranging and 
described in more detail below. 
 
AMPK suppresses synthesis of fatty acids, cholesterol, and proteins. 
Acetyl-CoA carboxylase (ACC) is the rate-limiting enzyme in fatty acid synthesis 
and is directly regulated by AMPK [47-50, 52-56]. When phosphorylated, ACC is 
inactivated and therefore unable to catalyze the formation of malonyl-CoA, a 
compound involved in fatty acid synthesis [47, 53, 56]. AMPK also regulates 
cholesterol synthesis by phosphorylating and inhibiting 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR) [47-50, 52, 54-56]. Finally, AMPK 
suppresses protein synthesis by decreasing flux through the mammalian target of 
rapamycin 1 (mTORC1) by activating the tuberous sclerosis complex 2 (TSC2) 
and inhibiting raptor [47-50, 53-56]. Inactivation of mTORC1 suppresses both the 
initiation and elongation steps in protein translation [56]. 
 
AMPK upregulates ATP production through fatty acid oxidation and 
glycolysis. AMPK-induced downregulation of malonyl-CoA leads to stimulation of 
carnitine palmitoyltransferase 1 (CPT1), an enzyme that facilitates transportation 
of fatty acids from the cytoplasm into the mitochondrial matrix where they are 
oxidized to produce energy [47, 48, 51-53, 56]. In addition, AMPK upregulates 
mitochondrial biogenesis [47, 56]. AMPK promotes fusion of the glucose 
transporter type 4 (GLUT-4) with the cell membrane, leading to an increase in 
intracellular glucose levels [47, 48, 52, 53, 56]. AMPK also stimulates glycolysis 
by activating phosphofructokinase-2, an enzyme that leads to the production of 
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fructose-2,6-bisphosphate [48, 53, 56]. Phosphofructokinase-1 is a glycolytic 
enzyme that is allosterically activated by fructose-2,6-bisphosphate [48, 56]. 
 
1.5.2 Effect on Autophagy 
 
AMPK is also able to regulate the induction of autophagy, which is a 
process by which cells consume damaged or unneeded organelles for energy to 
promote survival [45]. When cells are energy-starved or experience stress, 
AMPK initiates autophagy by phosphorylating and activating the enzyme Unc-51 
like autophagy activating kinase 1 (ULK1) [45]. AMPK also stimulates autophagy 
by decreasing flux through mTOR, a negative mediator of ULK1 [53]. Finally, 
AMPK promotes autophagy by regulating structures that contain vacuolar protein 
sorting 34 (VPS34), which are involved with autophagosome formation [53]. By 
promoting autophagy, AMPK prevents cells from undergoing apoptosis and 
thereby provides a direct survival advantage.  
 
1.6 AMPK in TNBC 
 
While AMPK is known to regulate metabolism in normal tissue, it is also 
associated with disease progression, cellular proliferation, and metabolism in 
TNBC. AMPK expression was higher in TNBC compared to other breast cancer 
subtypes or normal cells [59, 60]. Moreover, AMPK expression was increased in 
breast cancers larger than 2 centimeters or breast tumors with advanced stage 
[61]. Furthermore, increased AMPK expression was associated with lower OS 
and DFS in TNBC [60]. Upregulation of AMPK in TNBC cells increased glucose 
uptake, glycolytic flux, proliferation in vitro, and tumor growth in vivo [60]. 
Silencing of AMPK in TNBC cells led to similar results—decreased flux through 
glycolysis and a reduction in in vivo tumor growth [62]. Taken together, these 
findings indicate that AMPK promotes TNBC growth by stimulating ATP 
production through glycolysis. However, distinctions have not been made 
between the α1 and α2 isoforms in TNBC. AMPKα2 has previously been shown 
to suppress estrogen receptor-positive breast cancer growth by inducing G1 cell 
cycle arrest and promoting apoptosis [63]. Furthermore, AMPKα2 reduces growth 
of bladder cancer and hepatocellular carcinoma through p27 and p53, 
respectively [64, 65]. It is possible that the α2 isoform has a similar function in 
TNBC, but further work is needed to establish the roles of each individual 
isoform. 
 
1.6.1 AMPK as a Chemotherapeutic Target 
 
Small molecules can activate AMPK to levels that are much higher than 
what normally occurs in a cell or tissue. When this happens, AMPK starts 
suppressing cellular growth. At such an elevated level, AMPK can prevent 
anabolism, reduce cellular proliferation, decrease flux through the mTOR 
pathway, and induce apoptotic cell death [66-75]. However, the most well-known 
AMPK activators—including AICAR and 2-deoxyglucose—lack sensitivity and 
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require dosing in the millimolar range [76]. Such high concentrations result in 
side effects that are difficult for patients to tolerate and have prevented these 
compounds from being translated to the clinic. In addition, many common AMPK 
activators have wide-ranging cellular effects and reduce proliferation in AMPK-
knockdown cells, indicating that these compounds target multiple pathways [76]. 
This lack of specificity is another drawback to the usefulness of AMPK activators 
in cancer patients. While AMPK activation is a promising therapeutic strategy for 
TNBC, there is a need to develop novel compounds with increased sensitivity 
and specificity. Recent efforts have focused on this goal, and compounds such 
as OSU-53 and RL-71 activate AMPK and reduce proliferation in the micromolar 
range [67, 72]. Other studies have found that FDA-approved drugs—such as 
fluoxetine, tamoxifen, or metformin—can activate AMPK and may provide benefit 
in TNBC therapy [70, 71, 73-75]. While some progress has been made, there is 
still room for improvement. Future work should involve identifying novel 
compounds that activate AMPK at lower concentrations and with fewer side 
effects. 
 
1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-
(trifluoromethoxy)phenyl)urea (FND-4b) is a novel compound synthesized at the 
University of Kentucky that can activate AMPK at low micromolar doses, making 
it substantially more sensitive than AICAR, 2-deoxyglucose, or metformin [77, 
78]. As a result, FND-4b may possess a much more favorable side effect profile 
than other AMPK activators. FND-4b has previously been shown to suppress 
proliferation of colorectal cancer cells, but its effects have not been tested in 
TNBC [77].  
 
1.6.2 AMPK as a Radiosensitizer 
 
AMPK also plays an important role in mediating the cellular response to 
radiotherapy. Radiation exposure induced activation of AMPK in lung, prostate, 
breast, and colorectal cancer cells and also increased total AMPK levels in lung 
cancer cells [45, 79-81]. Levels of phosphorylated AMPK were increased in both 
the nucleus and cytoplasm in lung cancer cells after irradiation [79]. However, 
AMPK’s impact on cell survival after radiotherapy is complex and varies among 
tumor types. In certain cancers, AMPK activation potentiates radiation damage. 
Activation of AMPK with metformin led to mTOR inhibition and increased 
sensitivity to radiation in estrogen receptor-positive breast cancer cells [82]. In 
esophageal cancer, metformin also induced cell cycle arrest, reduced mTOR 
signaling, and enhanced radiation-induced decreases in survival [83]. 
Administration of metformin also further reduced survival of lung cancer cells 
after radiation exposure [79]. 
 
Inhibition of AMPK sensitized other cancers to the effects of radiotherapy. 
AMPK mediated the autophagy induction in response to radiation in esophageal 
and nasopharyngeal cancers [84, 85]. Furthermore, AMPK inhibition with 
compound C sensitized these cells to the effects of radiation [84, 85]. In 
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radiation-resistant colorectal cancer, expression of phosphorylated and total 
AMPK were upregulated [86]. Silencing or inhibiting AMPK overcame this 
resistance and potentiated radiation-induced death [86]. However, the impact of 
AMPK signaling on TNBC survival after radiation exposure is unknown and 
needs further study. 
 
Inhibiting AMPK function may sensitize TNBC cells to radiation through 
two mechanisms. First, knockdown of AMPK could limit ATP production in TNBC 
cells. Rates of catabolic processes—such as glycolysis or fatty acid oxidation—
may decline, while rates of anabolic processes—such as fatty acid synthesis—
may increase. This could lead to an imbalance of the cellular ATP/AMP ratio. 
Radiation induces aerobic glycolysis, and limiting energy mobilization through 
glycolysis may prevent cells from mounting an adequate survival response [87]. 
Moreover, DNA repair is an energy-intensive process and may be ineffective 
without sufficient resources. If damaged DNA is not fixed, then cells will undergo 
apoptosis. In addition, AMPK inhibition could suppress autophagy induction in 
TNBC cells that have been exposed to radiation. With the autophagy pathway 
diminished, damaged cells will be less likely to survive the stress conditions from 
radiotherapy. This could also lead to an increase in apoptosis induction. 
 
1.6.3 Effect of AMPK on Metastasis 
 
AMPK’s ability to mobilize energy may help cells metastasize to distant 
organs. In particular, cells that have detached from a matrix cannot import 
glucose from their environment and must instead generate ATP from other 
pathways [88]. Moreover, fatty acid oxidation and lipid synthesis—both of which 
are regulated by AMPK—can promote metastasis [89]. AMPK isoforms affect 
TNBC metastasis in an isoform-dependent manner [90, 91]. AMPKα1 has been 
shown to suppress distant spread of TNBC, while AMPKα2 promotes TNBC 
metastasis [90, 91]. However, the specific steps in the metastatic process that 
are regulated by AMPKα isoforms are unclear.  
 
1.7 Akt Signaling and Function 
 
 Akt is a downstream effector of phosphatidylinositol-3 kinase (PI3K) that 
can control signaling through the mTOR pathway and is composed of three 
isoforms: Akt1, Akt2, and Akt3 [92, 93]. Akt1 is widely expressed in the body and 
can be mutated or amplified in cancers [92, 93]. Akt2 has a more limited 
distribution and has high expression in adipocytes and muscles [92]. However, 
Akt2 is more frequently amplified in cancers than Akt1 [92]. Akt3 has a very 
limited distribution with the most expression in the brain and the testes [92, 94]. 
All three isoforms have a similar structure: a pleckstrin homology domain, a 
helical region, a kinase domain, and a regulatory motif [92]. However, they differ 
slightly in the location of the phosphorylation residues in the kinase and 
regulatory domains [92]. Akt1 is activated by phosphorylation of Thr308 in the 
kinase domain; in Akt2 and Akt3, this residue is Thr309 and Thr305, respectively 
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[92, 94]. Akt1 activation is also promoted by phosphorylation of Serine 473 
(Ser473) in the regulatory motif; in Akt2 and Akt3, this residue is Ser474 and 
Ser472, respectively [92, 95]. 
 
Akt has wide-ranging effects in the body and impacts metabolism, protein 
translation, proliferation, survival, and angiogenesis through a variety of 
downstream effectors [92]. For instance, Akt impacts protein translation by 
regulating mTOR and TSC2, and it controls metabolism through effects on insulin 
receptor substrate 1 (IRS1) and glycogen synthase kinase 3 (GSK3) [92]. Akt 
also influences proliferation through effects on cyclin-dependent kinase inhibitor 
1 and cyclin-dependent kinase inhibitor 1B [92]. Moreover, Akt impacts cellular 
survival by regulating Forkhead box protein O1 (FOXO1), pro-caspase 9, and 
BAD [92]. Finally, Akt affects angiogenesis through nitric oxide synthase 3 
(NOS3) [92]. As a result of this extensive signaling, Akt plays a role in diabetes, 
cardiovascular disease, and neoplasia [92]. 
 
1.8 Akt in TNBC 
 
 The PI3K signaling pathway is the most frequently altered pathway in 
breast cancer [96]. Alterations are also common in TNBC and are found in 29.8% 
of cases [97]. In particular, activating mutations in the PI3K catalytic subunit α 
(p110α) are the most frequent in breast cancer [96]. Mutations in p110α are 
present in 23.7% of TNBC cases [96]. This suggests that signaling through Akt 
may be upregulated in a substantial number of TNBC tumors. Consequently, 
there may be clinical benefit in targeting Akt signaling to enhance current therapy 
or reduce metastatic spread. 
 
1.8.1 Akt as a Radiosensitizer 
 
The capacity of Akt to promote cellular survival could indicate that it plays 
an important role in the cellular response to radiation-induced stress. The 
PI3K/Akt/mTOR signaling pathway has been targeted pharmacologically to 
enhance the efficacy of radiotherapy in estrogen receptor-positive and TNBC 
cells [98-102]. Moreover, ectopic expression of Akt1 has been shown to promote 
radiation resistance in estrogen receptor-positive breast cancer cells [103]. 
However, specific Akt isoforms have not been targeted to induce 
radiosensitization in TNBC. Moreover, combined suppression of AMPKα and Akt 
isoforms to enhance radiotherapy in TNBC cells has not been attempted. 
 
1.8.2 Effect of Akt on Metastasis 
 
Akt’s ability to regulate cellular metabolism and survival suggests that it 
may have a prominent role in controlling metastatic spread of TNBC tumors. 
Prior studies have analyzed the role of Akt isoforms in breast cancer metastasis. 
Akt1 has been shown to suppress metastasis in estrogen receptor-positive and 
HER2-amplified breast cancers [104-106]. Conversely, Akt2 promotes metastasis 
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of both estrogen receptor-positive and HER2-amplified breast cancers [105, 106]. 
However, the effect of Akt isoforms on TNBC metastasis is unknown. In addition, 
combined inhibition of AMPKα and Akt isoforms to reduce TNBC metastasis has 
not previously been attempted. 
 
1.9 Hypothesis 
 
This project was undertaken with the goal of understanding whether 
AMPK and Akt can be targeted to improve TNBC therapy and reduce TNBC 
metastasis. The hypothesis is that: (1) AMPK activation with the novel compound 
FND-4b will reduce proliferation of TNBC cells, (2) silencing AMPKα and Akt 
isoforms will enhance radiation-induced apoptosis in TNBC cells, and (3) 
suppression of AMPKα and Akt isoforms will reduce TNBC metastasis. 
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Figure 1.1 TNBC is primarily composed of four subtypes. 
TNBC is a heterogeneous disease that can be separated into four main 
subtypes. The basal-like 1 (BL1) subtype is the most common and comprises 
35% of cases. The mesenchymal (M) subtype is the next most common and 
makes up 25% of cases. The basal-like 2 (BL2) subtype is the third most 
common and comprises 22% of cases. The luminal androgen receptor (LAR) 
subtype is the least common and makes up 16% of cases. A small minority of 
cases (2%) do not fit into any of the four main categories and are considered 
unclassified. Data to prepare this graph were obtained from [13]. 
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Figure 1.2 Treatment protocol for stage II and III TNBC patients. 
Patients with stage II or III TNBC often receive NAC consisting of an 
anthracycline, a taxane, and/or a cyclophosphamide prior to surgery. Patients will 
then receive either a lumpectomy or a mastectomy. At the time of surgery, a 
pathologist determines whether a patient has achieved pCR or still has RD. 
Those who reach pCR usually receive radiation therapy and are then monitored. 
Patients who still have RD normally receive radiation therapy followed by 
adjuvant chemotherapy (capecitabine). Those patients who have RD after 
receiving NAC have an increased risk of recurrence and decreased survival. 
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CHAPTER 2. INDUCTION OF AMPK ACTIVATION BY N,N’-DIARYLUREA 
FND-4B DECREASES GROWTH AND INCREASES APOPTOSIS IN TRIPLE 
NEGATIVE AND ESTROGEN-RECEPTOR POSITIVE BREAST CANCERS 
 
2.1 Abstract 
 
Purpose: Triple negative breast cancer (TNBC) is the most lethal and 
aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a 
major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-
((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a 
novel AMPK activator that inhibits growth and induces apoptosis in colon cancer. 
The purpose of this project was to test the effects of FND-4b on AMPK activation, 
proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC. 
Materials and methods: (i) Estrogen-receptor positive breast cancer 
(ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast 
cancer stem cells were treated with FND-4b for 24h. Immunoblot analysis 
assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin 
D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed 
after treating ER+BC and TNBC cells with FND-4b for 72h. Proliferation was also 
assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA 
assays were performed after treating ER+BC and TNBC cells with FND-4b for 
72h. 
Results: (i) FND-4b increased AMPK activation with concomitant 
decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) 
FND-4b decreased proliferation in all cells, while dose-dependent growth 
decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were 
observed in ER+BC and the MDA-MB-231 cell line with FND-4b treatment. 
Conclusions: Our findings indicate that FND-4b decreases proliferation 
for a variety of breast cancers by activating AMPK and has notable effects on 
TNBC. The growth reductions were mediated through decreases in fatty acid 
synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1). ER+BC 
cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231 
cells still underwent apoptosis with higher dose treatment. Further development 
of FND compounds could result in a novel therapeutic for TNBC. 
 
2.2 Introduction 
 
Breast cancer is the most common cancer in women and the main cause 
of cancer-related death among women worldwide. In 2018 alone, there will be 
more than 266,000 newly diagnosed cases of breast cancer in women in the 
United States and almost 41,000 deaths [107]. Up to 30% of patients develop 
metastases, and 90% of deaths result from metastases to the lung, brain, or 
bone [2]. Breast cancer is a heterogeneous disease separable into three main 
types: estrogen-receptor positive breast cancer (ER+BC), HER2-amplified breast 
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cancer, and triple negative breast cancer (TNBC). Although TNBC comprises 
only 15-20% of total cases, it is the most lethal and aggressive of the three types 
[3, 4]. 
 
The principal characteristics of TNBC include: (1) reduced expression of 
the estrogen and progesterone receptors and (2) no overexpression of HER2. 
TNBC affects a younger patient population than the population afflicted with other 
types of breast cancer and leads to an increased risk of recurrence and 
metastases [3]. Not surprisingly, patients with recurrent TNBC have a worse 
prognosis than that for patients with recurrent forms of other breast cancers [3]. 
In addition, patients with TNBC have limited therapeutic options because their 
tumors lack the traditional steroid hormone receptors and HER2 amplification. 
Instead, patients usually receive a drug cocktail that includes an anthracycline 
antineoplastic agent, a DNA alkylating agent, and a taxane [3]. These 
chemotherapeutic agents are toxic to normal and cancer cells alike and result in 
serious side-effects that are difficult for patients to tolerate. Recent efforts have 
focused on developing therapies that specifically target cancer cells without 
affecting normal cells. Because oncogenic transformation requires major 
metabolic reprogramming to produce energy, redox cofactors, and molecules 
involved in DNA modification, new agents that target the increased metabolism 
within cancer tissue more than the metabolism in normal tissue are attractive 
therapeutic options [2]. 
 
AMP-activated protein kinase (AMPK) is a cellular energy sensor that has 
important implications in cancer progression [44, 45, 47-52, 54-57]. When 
activated by ATP depletion, the phosphorylated form of AMPK causes the 
following changes in TNBC: (1) inhibition of anabolic and oncogenic pathways, 
(2) attenuated mTOR signaling, (3) decreased cell proliferation, and (4) apoptosis 
[66-75]. Well-known AMPK activators, such as 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) and 2-deoxyglucose (2-DG), require high doses to affect 
cancer cell proliferation, which has led to their unsuccessful translation to the 
clinic for cancer therapy [50]. Among the attempts to produce new AMPK 
activators with increased sensitivity, the fluorinated N,N’-diarylureas (FNDs) 
serve as activators that lead to phosphorylated AMPK at low concentrations [77, 
78]. In particular, 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-
(trifluoromethoxy)phenyl)urea (FND-4b) inhibits growth and induces apoptosis in 
colorectal cancer cells, but its potential effects on other types of cancer remain 
unclear [77]. Because of the pressing need to develop new treatments for TNBC, 
we tested the effects of FND-4b on TNBC and compared the results with ER+BC. 
Importantly, we found that treatment with FND-4b led to AMPK activation, 
decreased cell cycle flux, and increased apoptosis in both subtypes. These 
findings indicate that FND compounds may be potential therapeutic options for 
TNBC. 
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2.3 Materials and methods 
 
2.3.1 Reagents, supplements, and antibodies 
 
1-(3-Chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-
(trifluoromethoxy)phenyl)urea (FND-4b) was synthesized and characterized as 
previously described [78]. Roswell Park Memorial Institute (RPMI) 1640 Medium 
and Eagle’s Minimum Essential Medium (EMEM) were purchased from Sigma-
Aldrich (St. Louis, MO). Dulbecco’s Modified Eagle Medium (DMEM) was from 
Corning (Corning, NY). Human breast cancer stem cell complete growth medium 
was from Celprogen (Torrance, CA). MEM non-essential amino acid solution 
(100x), sodium pyruvate solution (100 mM), insulin solution (10 mg/mL), 
penicillin-streptomycin (100x) (P/S), and fetal bovine serum (FBS) were from 
Sigma-Aldrich. 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) was 
from Abcam (Cambridge, MA). Antibodies for pAMPKα (Thr172), total AMPKα, 
phosphorylated acetyl-CoA carboxylase (ACC), total ACC, phosphorylated 
ribosomal protein S6, total S6, and PARP were from Cell Signaling Technology 
(CST; Danvers, MA). The cyclin D1 antibody was from Abcam. The beta-actin 
antibody was from Sigma-Aldrich. The secondary antibodies to rabbit and mouse 
were from Santa-Cruz. All relevant antibody information is in Table 1 below. The 
Sulforhodamine B (SRB) Cytotoxicity Assay was from G-Biosciences (St. Louis, 
MO). The Cell Death Detection ELISAPLUS assay was from Sigma-Aldrich. 
 
2.3.2 Cell culture 
 
MCF-7, T-47D, MDA-MB-231, HCC-1143, and HCC-1806 cells were 
purchased from ATCC, while breast cancer stem cells were purchased from 
Celprogen. MCF-7 cells were maintained in EMEM containing 10% FBS, 1% P/S, 
0.01 mg/mL insulin, 1x non-essential amino acids, and 1 mM sodium pyruvate. T-
47D cells were maintained in RPMI containing 10% FBS, 1% P/S, and 0.2 
Units/mL insulin. MDA-MB-231, HCC-1143, and HCC-1806 cells were 
maintained in RPMI with 10% FBS and 1% P/S. Breast cancer stem cells were 
maintained in breast cancer stem cell medium supplemented with 10% FBS and 
1% P/S. All cells were grown in an incubator at 37°C and 5% CO2. For cell 
treatments, 7x105 MCF-7 and T-47D cells or 8x105 MDA-MB-231, HCC-1806, 
and breast cancer stem cells were seeded in 6-well plates and incubated 
overnight. The medium was removed on the following day, and cells were treated 
with fresh medium that contained different concentrations of FND-4b (0, 1, 2.5, 5, 
10, and 20 µM) for 24 h before lysis. 
 
2.3.3 Western blot analysis 
 
After treatment, cells were scraped from the wells with 1x RIPA buffer 
containing serine protease inhibitor. The cells were lysed by incubating on ice for 
20 min and vortexing 10 sec every 5 min. The lysates were centrifuged at 14,000 
rpm and 4°C for 20 min, and the protein concentration was determined using the 
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Bradford method. The proteins were reduced and denatured by heating at 80°C 
for 10 min. An equal amount of protein was resolved on SDS-PAGE gels and 
transferred to PVDF membranes. The membranes were blocked with 10% milk 
before overnight incubation with primary antibodies at 4°C. On the following day, 
the membranes were washed with Tris buffered saline with 0.1% tween-20 
(TBST) for 5 min and again for 10 min. The membranes were subsequently 
incubated with the appropriate secondary antibody for 30 min at room 
temperature. The membranes were then washed with TBST for 15 min and again 
for 20 min. Proteins were visualized with Amersham ECL (GE Healthcare) or 
Immobilon (Millipore). Membranes were stripped and reprobed as necessary. 
 
2.3.4 Cell counting assay 
 
Cells (1x105) were seeded in 6-well plates and incubated overnight. The 
medium was removed on the following day, and cells were grown in fresh 
medium that contained either: (a) 0 or 5 µM FND-4b or (b) 0 or 1 mM AICAR for 
72 h. Cells were then washed with PBS, trypsinized, and counted with a 
Beckman-Coulter cell counter. 
 
2.3.5 SRB growth assay 
 
Cells (5x103 in 100 µL) were seeded in 96-well plates and incubated 
overnight. On the following day, fresh media was prepared to contain twice the 
desired concentrations of FND-4b (i.e., 5, 10, 20, and 40 µM). Then 100 µL of the 
new media solutions were added to the wells without removing the old media; 
this yielded 200 µL per well and halved the FND-4b concentrations. Cells were 
grown in the media with different final concentrations of FND-4b (0, 2.5, 5, 10, 
and 20 µM) for 72 h before the proteins were fixed at 4°C for 1 h. The wells were 
washed 3 times with water and then dried for 30 min. The SRB dye solution 
(0.4%) was added to the wells and incubated for 30 min. The excess dye was 
washed off with 1% acetic acid, and the wells were allowed to air dry. The dye 
was solubilized with a 10 mM Tris solution, and the absorbance was measured at 
565 nm or—if the readings were outside of the instrument’s linear range—at 490 
nm. 
 
2.3.6 Cell Death Detection ELISAPLUS assay 
 
Cells (5x103 in 100 µL) were seeded in 96-well plates and incubated 
overnight. On the following day, fresh media was prepared to contain twice the 
desired concentrations of FND-4b (i.e., 5, 10, and 20 µM). Then 100 µL of the 
new media solutions were added to the wells without removing the old media; 
this yielded 200 µL per well and halved the FND-4b concentrations. Cells were 
cultured in the media with different final concentrations of FND-4b (0, 2.5, 5, and 
10 µM) for 72 h. Cells were then centrifuged at 200 x g for 10 min and lysed for 
30 min with shaking. The lysates were centrifuged at 200 x g for 10 min, and 20 
µL of supernatant was transferred to streptavidin-coated wells. Then 80 µL of the 
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immunoreagent (anti-histone biotin and anti-DNA peroxidase) was added to the 
streptavidin-coated wells. The plates were shaken for 2 h at room temperature 
before the wells were rinsed three times with incubation buffer. Color change was 
initiated by adding the substrate ABTS to the wells, and the plates were shaken 
until the color change was sufficient for photometric analysis. After adding the 
ABTS Stop Solution, absorbance was measured at 405 nm. 
 
2.3.7 Statistical analysis 
 
Comparisons of SRB growth and ELISA assays across non-treated and 
different dose groups of FND-4b were performed using analysis of variance 
(ANOVA) with test for linear trend across dose levels. Pairwise comparisons of 
each FND-4b dose level versus non-treated group were performed within the 
ANOVA model with Holm's p-value adjustment for multiple testing. Comparisons 
of baseline ELISA values between HCC-1806 cells and other cell lines were 
performed using ANOVA with least squares means and adjustment for multiple 
comparisons. Comparisons of cell counting assays between control and FND-4b- 
or AICAR-treated groups were performed using two-sample t-tests with 
homogeneity of variance assessed for the use of the t-test for two group 
comparisons. Analyses were performed on data normalized with the non-treated 
group for the SRB growth and cell counting assays and on the raw data for the 
ELISA assays. In all experiments, p-values less than 0.05 were considered 
significant. 
 
2.4 Results 
 
2.4.1 Analysis of pAMPKα expression in breast cancer subtypes 
 
Prior work has suggested that TNBC cell lines and tissues have higher 
levels of phosphorylated and total forms of AMPKα than non-TNBC cells and 
tissues [59]. Consequently, we compared levels of pAMPKα and total AMPKα in 
TNBC and ER+BC cells using western blotting. We found no difference in levels 
of phosphorylated or total AMPKα between two ER+BC cell lines (MCF-7 and T-
47D) and three TNBC cell lines (MDA-MB-231, HCC-1143, and HCC-1806) 
(Figure 2.1). 
 
2.4.2 FND-4b activated AMPKα and downstream signaling pathways in breast 
cancer 
 
Because FND-4b activated AMPKα in colon cancer cells, we investigated 
its effects in several subtypes of breast cancer [77]. In particular, MCF-7, T-47D, 
MDA-MB-231, HCC-1806, and breast cancer stem cells were treated with fresh 
medium containing a range of FND-4b concentrations (0, 1, 2.5, 5, 10, and 20 
µM) for 24 h. Protein levels of phosphorylated and total forms of AMPKα, acetyl-
CoA carboxylase (ACC), and ribosomal protein S6, cyclin D1, and cleaved PARP 
were measured with immunoblotting. ACC and S6 were selected for analysis 
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because they are downstream effectors of AMPKα that are phosphorylated and 
dephosphorylated, respectively, with AMPKα activation. As expected based on 
prior work, FND-4b treatment increased levels of pAMPKα in all five cell lines 
(Figure 2.2) [77]. Consistent with this result, increases in pACC and decreases in 
pS6 were also noted. Cyclin D1, an AMPKα-regulated marker for flux through the 
cell cycle, was decreased in all cell lines treated with FND-4b. Increases in the 
apoptotic indicator cleaved PARP were observed in MCF-7, MDA-MB-231, and 
HCC-1806 cells with AMPKα activation. FND-4b concentrations less than 5 µM 
yielded minimal effects on AMPK signaling, but the 5 µM dose yielded robust 
effects in all cells tested. The HCC-1806 cells were notable because AMPKα 
activation spiked with 5 µM FND-4b treatment and then declined with 
concentrations higher than 5 µM. Taken together, these results indicate that 
FND-4b activates AMPKα and its downstream signaling pathways in TNBC, 
ER+BC, and breast cancer stem cells. 
 
2.4.3 FND-4b decreased growth of breast cancer subtypes in a dose-dependent 
fashion 
 
AMPKα has been implicated as a tumor suppressor in breast cancer [66-
75]. Since FND-4b activated AMPKα, we measured its effects on the growth of 
breast cancer cells and compared with AICAR—a known AMPK activator. Cell 
counting assays showed that treatment at 5 µM FND-4b for 72 h resulted in 
significant growth inhibition of MCF-7, T-47D, MDA-MB-231, HCC-1806, and 
breast cancer stem cells (Figure 2.3A). Similar decreases occurred in all breast 
cancer subtypes with 5 µM treatment. Treatment at a much higher concentration 
of AICAR (1 mM) for 72 h yielded growth reductions similar to FND-4b among all 
subtypes (Figure 2.3B). The most striking differences were that MCF-7 cells were 
more sensitive to FND-4b while HCC-1806 cells were more responsive to 
AICAR. Only small differences were noted among T-47D, MDA-MB-231, and 
breast cancer stem cells. In addition, SRB growth assays indicated that treatment 
at various FND-4b concentrations (2.5, 5, 10, and 20 µM) for 72 h yielded 
significant dose-dependent decreases in proliferation of MCF-7, T-47D, MDA-
MB-231, and HCC-1806 cells (Figure 2.3C). ER+BC cells were more sensitive 
than TNBC cells to FND-4b at 2.5 µM, but the reductions were similar at higher 
concentrations. Similar growth inhibition at the 5 µM dosage between ER+BC 
and TNBC is consistent with the results from the cell counting assays. Taken 
together, these results illustrate that activation of AMPKα with FND-4b resulted in 
dose-dependent decreases in growth in ER+BC and TNBC. 
 
2.4.4 FND-4b increased apoptosis in ER+BC and TNBC 
 
While FND-4b’s major effect is on cell growth, its treatment also increased 
apoptosis in colon cancer [77]. Therefore, we investigated apoptosis induction in 
breast cancer cells. As previously mentioned, treatment with FND-4b resulted in 
increased levels of cleaved PARP, a marker of apoptosis, in MDA-MB-231, HCC-
1806, and MCF-7 cells (see Figure 2.2). We also measured apoptosis with 
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ELISA cell death assays that are more sensitive than western blotting assays. 
Significant increases in apoptosis were found in MCF-7 and T-47D cells—with 
MCF-7 cells being more sensitive (Figure 2.4A). Apoptosis was significantly 
increased in MDA-MB-231 cells with treatment at 10 µM FND-4b, but apoptosis 
in HCC-1806 cells was not increased (Figure 2.4A). Finally, to determine whether 
higher baseline pAMPK levels affect apoptosis in these cells, we compared the 
basal rates of apoptosis among the four cell lines used in the ELISA assays. 
HCC-1806 cells, which had the lowest pAMPK levels at baseline (Figure 2.1), 
had a much higher basal apoptotic rate than the other three cell lines (Figure 
2.4B). This indicates that higher baseline levels of pAMPK do not increase the 
basal apoptotic rate. The elevated basal level of apoptosis in HCC-1806 cells is 
likely the reason why FND-4b was unable to induce apoptosis in this cell line. 
FND-4b’s ability to suppress growth of HCC-1806 cells resulted in fewer cells in 
the treated wells compared to the control wells. As a result, there were less cells 
that could have undergone apoptosis—resulting in lower readings in the treated 
wells. 
 
2.5 Discussion 
 
The connection between AMPK activation and the inhibition of cancer cell 
growth prompted our interest in targeting AMPK and its downstream signaling 
pathways. AMPK activators such as AICAR and 2-DG have limited utility for 
patient care due to their high dose requirements [50]. We focused on novel 
small-molecule agents that activated AMPK at low concentrations and that stood 
a greater chance than these well-known AMPK activators of progressing toward 
the clinic. In this project, we examined the effects of the AMPK activator FND-4b 
to determine its effects on ER+BC, TNBC, and breast cancer stem cells. FND-4b 
previously suppressed the growth of colorectal cancer cells and stem cells 
through ac5tivation of AMPK in the low micromolar range without affecting 
signaling through the Akt or ERK pathways [77, 78]. We found that treatment with 
FND-4b resulted in dose-dependent increases in AMPK activation in both breast 
cancer subtypes and in the stem cells.  
 
Other investigators have also focused on discovering novel AMPK 
activators or repurposing current drugs that activate AMPK for breast cancer 
therapy. OSU-53 and RL-71 activated AMPK and exerted anti-tumor effects in 
TNBC at low micromolar doses [67, 72]. In addition, demethoxycurcumin (20 µM) 
resulted in AMPK activation and large decreases in TNBC and ER+BC cell 
proliferation [68]. Finally, treatment of TNBC with the anti-depressant fluoxetine 
(0.5 µM) caused AMPK activation and substantial reductions in cellular viability 
[71]. Taken together, these studies and ours suggest the merit in targeting the 
AMPK signaling pathway for the treatment of breast cancer.  
 
We found that low micromolar concentrations of FND-4b substantially 
reduced the growth of TNBC. The decreases in proliferation that were induced by 
5 µM FND-4b were similar to those caused by a much higher concentration of 
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AICAR (1 mM). Although HCC-1806 cells were more responsive to AICAR in cell 
counting assays, slightly higher concentrations of FND-4b (10 or 20 µM) should 
suppress HCC-1806 growth more than 1 mM AICAR. The substantial growth 
reductions that we found are particularly important because of the inherent 
aggressiveness of TNBC that has higher rates of recurrence and metastasis than 
other breast cancer subtypes [3]. The seriousness of TNBC is further amplified 
by the fact that most breast cancer deaths result from metastatic lesions [2]. The 
difficulty in developing treatments for TNBC is due to the lack of the estrogen 
receptor and HER2 amplification. Drugs that target these proteins, such as 
trastuzumab and tamoxifen, are ineffective in TNBC. Instead, patients with TNBC 
typically receive a drug cocktail that damages normal cells in addition to the 
tumor and leads to significant side effects. Current efforts are focused on 
developing drugs that specifically target proteins or pathways that are exclusively 
altered in TNBC. Since expression of AMPK and pAMPK is lower in breast 
cancer than normal tissue, this signaling pathway attracted our attention as an 
option for targeted therapy [61, 108, 109]. 
 
AMPK activation resulted in substantial decreases in cell proliferation in all 
breast cancer subtypes that were tested. These reductions in growth were due to 
AMPK’s ability to regulate the cell cycle both directly and indirectly. Directly, 
AMPK activation can attenuate levels of cyclin D1, an important protein that 
controls cell cycle arrest during the G1 phase [110]. Prior work in ovarian cancer 
has suggested that AMPK activation causes degradation of cyclin D1 through a 
pathway involving glycogen synthase kinase 3β [110]. Once cyclin D1 is 
degraded, cells are prevented from progressing past the G1 phase [110]. We 
found that FND-4b-induced AMPK activation resulted in substantial decreases in 
cyclin D1 expression, resulting in cell cycle arrest. Indirectly, AMPK activation 
can affect the cell cycle through effects on mTOR and cellular metabolism. 
AMPK downregulates flux through the mTOR pathway, which can control the cell 
cycle through its downstream effectors S6 kinase 1 (S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 [111]. In our study, we measured 
mTOR activity by blotting for levels of phosphorylated ribosomal protein S6, 
which is downstream from S6K1. We found decreases in S6 phosphorylation with 
FND-4b-induced AMPK activation, indicating less mTOR flux and cell cycle 
progression. Additionally, AMPK affects cell metabolism by phosphorylating and 
inhibiting ACC, which is the rate-limiting step in fatty acid synthesis. As a result, 
de novo lipogenesis is inhibited. Fatty acids are required for progression through 
the cell cycle—notably, during the G1-S and G2-M phases—and in their absence, 
cells will be unable to complete mitosis [54]. Instead they will be arrested at the 
G2-M checkpoint [54]. We showed that FND-4b-induced AMPK activation led to 
increased ACC phosphorylation, signifying less fatty acid synthesis and flux 
through the cell cycle. 
 
In addition to inducing cell cycle arrest, AMPK can also act as a tumor 
suppressor by causing apoptosis [108]. We found that FND-4b causes apoptosis 
in a dose-dependent manner in ER+BC cells with ELISA cell death assays. We 
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also showed clear increases in levels of cleaved PARP—an apoptotic indicator—
in MCF-7 cells. TNBC cells were more resistant to apoptosis from FND-4b, but 
there was apoptosis in MDA-MB-231 cells with 10 µM treatment. Additionally, we 
found increases in cleaved PARP in MDA-MB-231 and HCC-1806 cells with 
western blot. Taken together, these data indicate that ER+BC cells are more 
susceptible to FND-4b-induced apoptosis than TNBC. However, as suggested in 
previous work, the effects of FND-4b on cell cycle progression are more 
pronounced and consistent than on apoptosis [77]. 
 
2.6 Conclusions 
 
We have shown that the novel compound FND-4b can activate AMPK in 
ER+BC, TNBC, and breast cancer stem cells. In addition, treatment with this 
compound can dose-dependently decrease proliferation and increase apoptosis 
in breast cancer cells. The effects on cellular growth are mediated via decreased 
cell cycle flux—as evidenced by reductions in cyclin D1 levels—and suppression 
of fatty acid synthesis and mTOR signaling. With such profound effects on 
proliferation, further development of FND compounds could lead to their inclusion 
in TNBC treatment regimens. 
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Table 2.1 Primary and Secondary Antibody Information. 
Antibody Monoclonal 
vs. 
Polyclonal 
Host 
Species 
Dilution Supplier Catalogue 
Number 
pAMPKα Monoclonal Rabbit 1:500 CST 2535 
Total 
AMPKα 
Polyclonal Rabbit 1:1000 CST 2532 
pACC Polyclonal Rabbit 1:1000 CST 3661 
Total ACC Monoclonal Rabbit 1:1000 CST 3676 
pS6 Polyclonal Rabbit 1:1000 CST 2211 
Total S6 Monoclonal Rabbit 1:1000 CST 2217 
Cyclin D1 Monoclonal Rabbit 1:2500 Abcam ab134175 
PARP Monoclonal Rabbit 1:1000 CST 9532 
Beta-actin Monoclonal Mouse 1:10000 Sigma-
Aldrich 
A1978 
Rabbit - Goat 1:10000 Santa 
Cruz 
sc-2054 
Mouse - Goat 1:10000 Santa 
Cruz 
sc-2055 
 
 
 
 
 
 
 
 
 
24 
 
Figure 2.1 Examination of pAMPKα levels in breast cancer subtypes. 
Equal numbers of MCF-7, T-47D, HCC-1143, MDA-MB-231, and HCC-1806 cells 
were incubated overnight before cell lysis. Western blot analyses were performed 
for total and phosphorylated forms of AMPKα and ACC. Beta-actin was used as 
the loading control. 
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Figure 2.2 FND-4b activated AMPKα and its downstream signaling 
pathways in a dose-dependent manner in breast cancer. 
Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806 or breast cancer 
stem cells were treated with fresh medium that contained different FND-4b 
concentrations (0, 1, 2.5, 5, 10, and 20 µM) for 24 h. Western blot analysis was 
then performed for phosphorylated and total forms of AMPKα, ACC, and S6 as 
well as cyclin D1 and cleaved PARP. Beta-actin was used as the loading control. 
Treatment of the HCC-1806 cell line was repeated to confirm the spike in AMPKα 
activation at the 5 µM dosage with subsequent decreases at higher 
concentrations. 
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Figure 2.3 AMPKα activation with FND-4b decreased proliferation of breast 
cancer cells with similar efficacy to AICAR. 
(A) Equal numbers of MCF-7, T-47D, MDA-MB-231, HCC-1806, or breast cancer 
stem cells were grown in medium containing 0 or 5 µM FND-4b for 72 h followed 
by cell counting. (B) The same procedure described in (A) was followed with the 
exception of growing cells in medium containing 0 or 1 mM AICAR instead. (C) 
MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were grown in medium 
containing different concentrations of FND-4b (0, 2.5, 5, 10, and 20 µM) for 72 h 
before SRB growth assays were performed. Data are presented as mean ± SD 
from experiments performed in triplicate (cell counting) or sextuplicate (SRB 
assays) and are representative of three independent experiments. * indicates p-
value < 0.01. 
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Figure 2.4 AMPKα activation with FND-4b increased apoptosis of breast 
cancer cells. 
(A) Equal numbers of MCF-7, T-47D, MDA-MB-231, or HCC-1806 cells were 
cultured in medium containing different concentrations of FND-4b (0, 2.5, 5, and 
10 µM) for 72 h before ELISA cell death assays were performed. (B) The basal 
apoptotic rates of MCF-7, T-47D, MDA-MB-231, and HCC-1806 cells were 
compared using the control data from the ELISA cell death assays in (A). Data 
are presented as mean ± SD from an experiment performed in triplicate and are 
representative of three independent experiments. * indicates p-value < 0.001. 
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CHAPTER 3. TARGETING PI3K AND AMPKα SIGNALING ALONE OR IN 
COMBINATION TO ENHANCE RADIOSENSITIVITY OF TRIPLE NEGATIVE 
BREAST CANCER 
 
3.1 Abstract 
 
Triple negative breast cancer (TNBC) is the most aggressive breast 
cancer subtype and is characterized by poor survival. Radiotherapy plays an 
important role in treating TNBC. The purpose of this study was to determine 
whether inhibiting the AMP-activated protein kinase (AMPK) and 
phosphatidylinositol 3-kinase (PI3K) pathways alone or in combination 
potentiates radiotherapy in TNBC. AMPKα1 and AMPKα2 knockdown diminished 
cyclin D1 expression and induced G1 cell cycle arrest but did not induce 
apoptosis alone or in combination with radiotherapy. Next, we analyzed the role 
of PI3K p85α, p85β, p110α, p110β, Akt1, and Akt2 proteins on TNBC cell cycle 
progression and apoptosis induction. Akt1 and p110α knockdown diminished 
cyclin D1 expression and induced apoptosis. Silencing Akt1 promoted synergistic 
apoptosis induction during radiotherapy and further reduced survival after 
radiation. Treatment with the Akt inhibitor, MK-2206 48 h after radiotherapy 
decreased Akt1 levels and potentiated radiation-induced apoptosis. Together, 
our results demonstrate that AMPKα, p110α, and Akt1 promote TNBC 
proliferation and that Akt1 is a key regulator of radiosensitivity in TNBC. 
Importantly, combining radiotherapy with the pharmacological inhibition of Akt1 
expression is a potentially promising approach for the treatment of TNBC. 
 
3.2 Introduction 
 
Breast cancer is the most common and second deadliest cancer among 
women worldwide [4]. The most aggressive subtype is triple negative breast 
cancer (TNBC), which makes up about 15-20% of cases [3, 4]. TNBC is 
characterized by a lack of expression of the estrogen receptor, progesterone 
receptor, and HER2 [2, 4]. It affects a younger patient population, metastasizes 
at a higher rate than other subtypes, and has a poor prognosis [3, 4]. Tumor 
analysis has revealed four separate subtypes of TNBC [13]. Due to this 
heterogeneity, the development of targeted therapies for TNBC has largely been 
unsuccessful [5]. Standard approaches involve chemotherapy, which can be 
combined with surgery and/or radiation, but improvements still need to be made 
[3, 4]. Radiosensitization, which involves combining radiotherapy with an agent 
that can potentiate its effects, is a potential advancement that warrants further 
study in TNBC. 
 
Radiation improves survival in TNBC patients [33, 34] by inducing single- 
and double-stranded DNA breaks through direct DNA damage or via the 
generation of free radicals [112-114]. Radiated cells respond to this by activating 
stress, survival, and metabolic pathways, and repair enzymes attempt to fix 
damaged DNA [112-114]. If the DNA is not successfully repaired, then the 
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apoptotic cascade will be induced and lead to cell death [112-114]. Blocking 
cellular pathways that control metabolism or survival may prevent cells from 
adequately repairing damaged DNA, thereby enhancing apoptosis induction and 
leading to radiosensitization. Two proteins that play important roles in 
metabolism and survival are AMP-activated protein kinase (AMPK) and 
phosphatidylinositol 3-kinase (PI3K), respectively. Furthermore, a double-
negative feedback loop exists between AMPK and Akt, a major downstream 
effector of PI3K, in breast cancer [115].  
 
AMPK is a heterotrimer that is made up of a catalytic subunit (α) and two 
regulatory subunits (β and γ) [44, 46-48, 50, 52, 53, 56]. The catalytic subunit 
consists of α1 and α2 isoforms [44, 46-48, 50, 52, 53, 56]. AMPK is a major 
metabolic regulator that is activated during low energy states and helps cells 
return to energy homeostasis by increasing ATP production and reducing ATP 
consumption [44, 46-48, 50, 52, 53, 56]. Radiotherapy induces cellular stress and 
has led to AMPK activation in cancer cells [80, 85]. Moreover, AMPK has 
provided a survival benefit in esophageal and nasopharyngeal carcinoma cells 
exposed to radiation by mediating autophagy induction [84, 85]. Furthermore, 
levels of phosphorylated and total AMPK were upregulated in radiation-resistant 
colon cancer cells and tissue—with AMPK knockdown sensitizing radiation-
resistant cells to radiotherapy [86]. PI3K is a heterodimer that promotes cellular 
growth and survival by activating Akt, which subsequently activates the 
mammalian target of rapamycin (mTOR) [92-95, 116]. PI3K is composed of a 
catalytic subunit (p110α or p110β) and a regulatory subunit (p85α or p85β) [93, 
95, 116]. Akt is composed of three isoforms: Akt1, Akt2, and Akt3 [92, 94]. The 
PI3K/Akt/mTOR pathway is the most altered pathway in breast cancer, and 
almost 30% of TNBC cases have PI3K alterations [96, 97]. Studies have 
indicated that 20-25% of these changes were due to mutations in PIK3CA, which 
is the gene for p110α [96, 97]. Since this signaling cascade promotes survival, it 
has also been targeted in efforts to induce radiosensitivity. Chemical inhibition of 
PI3K or mTOR signaling—alone or in combination—sensitized estrogen 
receptor-positive breast cancer and TNBC to radiotherapy [98-102]. In addition, 
ectopic expression of Akt1 promoted radioresistance in estrogen receptor-
positive breast cancer [103]. However, targeting individual AMPK isoforms, PI3K 
subunits, or Akt isoforms—alone or in combination—to enhance the effects of 
radiation in TNBC has not previously been done. 
 
 In the present study, we investigated the role of AMPK and the PI3K/Akt 
pathway in TNBC radiation sensitivity and examined whether combination 
therapy can improve treatment response to radiation therapy. We determined 
that both Akt1 and p110α promote proliferation and prevent apoptosis in TNBC 
cells. Next, we established that knockdown of Akt1 enhances radiation-induced 
apoptosis in TNBC cells and decreases survival of TNBC cells after radiation. 
Knockdown of AMPKα1 or AMPKα2 did not enhance radiation-induced apoptosis 
alone or in combination with Akt1 knockdown. Finally, we showed that treatment 
with the Akt inhibitor MK-2206 reduces Akt1 expression and promotes synergistic 
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apoptosis induction with radiotherapy in a schedule-dependent manner. 
Targeting Akt1 expression at the initiation of radiation-induced apoptosis could 
improve TNBC patient outcomes, reduce toxicity associated with PI3K/mTOR 
inhibition, and mitigate side effects from radiotherapy. 
 
3.3 Materials and methods 
 
3.3.1 Materials 
 
Roswell Park Memorial Institute (RPMI) 1640 medium was from Thermo 
Fisher (Waltham, MA). Dulbecco’s Modified Eagle Medium (DMEM) was from 
Corning (Corning, NY). DMEM/F12 was from Sigma-Aldrich (St. Louis, MO). 
Fetal bovine serum (FBS), 100x penicillin-streptomycin solution (PS), 10 mg/mL 
insulin solution, 100x non-essential amino acid solution, and Dulbecco’s 
Phosphate Buffered Saline (PBS) were from Sigma-Aldrich. Opti-MEM and 
Lipofectamine RNAiMAX were from Thermo Fisher. Protein Assay Dye was from 
Bio-Rad (Hercules, CA). Amersham ECL Prime Western Blotting Detection 
Reagent was from GE Healthcare Life Sciences (Chicago, IL). Immobilon 
Western Chemiluminescent HRP Substrate was from Millipore (Burlington, MA). 
Pooled siRNAs for AMPKα1 and AMPKα2 were from Santa Cruz Biotechnology 
(Dallas, TX). Pooled siRNAs for Akt1, Akt2, p110α, p110β, p85α, and p85β were 
from Thermo Fisher. The CytoscanTM SRB Cell Cytotoxicity Assay was from G-
Biosciences (St. Louis, MO). The Propidium Iodide Flow Cytometry Kit for Cell 
Cycle Analysis was from Abcam (Boston, MA). MK-2206 2HCl, A-674563, 
AZD5363, and Perifosine were from Cayman Chemical (Ann Arbor, MI). Primary 
antibodies used in this study include: Abcam: (1) AMPKα1, ab32047 (1:1000 for 
WB, 1:100 for IHC for PDXs, and 1:175 for IHC for whole tissue sections), (2) 
AMPKα2, ab3760 (1:1000 for WB, 1:200 for IHC for PDXs, and 1:300 for IHC for 
whole tissue sections), (3) Cyclin D1, ab134175 (1:2500 for WB); Cell Signaling 
Technology (Danvers, MA): (1) pAkt, #4060 (1:2000 for WB), (2) Akt1, #75692 
(1:1000 for WB), (3) Akt2, #3063 (1:1000 for WB), (4) p110α, #4249 (1:1000 for 
WB), (5) p110β, #3011 (1:1000 for WB), (6) Cleaved PARP, #5625 (1:1000 for 
WB), (7) Caspase-3, #9664 (1:1000 for WB), (8) p53, #2527 (1:1000 for WB), (9) 
pDNA-PKcs, #68716 (1:1000 for WB), (10) DNA-PKcs, #12311 (1:1000 for WB), 
(11) pAMPKα, #50081 (1:1000 for WB), and (12) AMPKα, #5831 (1:1000 for 
WB); Santa Cruz Biotechnology: (1) p85α, sc-71891 (1:1000 for WB), (2) p85β, 
sc-515646 (1:1000 for WB); and Sigma-Aldrich: β-actin (1:10,000 for WB). 
Secondary antibodies were from Santa Cruz Biotechnology. 
 
3.3.2 Cell Culture 
 
MDA-MB-175, MDA-MB-231, MDA-MB-453, MDA-MB-468, HCC-1143, 
HCC-1806, BT-20, BT-549, and HS-578T cells were from the American Type 
Culture Collection. All cells were cultured in a humidified incubator at 37°C and 
5% CO2. MDA-MB-231, MDA-MB-453, HCC-1143, and HCC-1806 cells were 
cultured in RPMI-1640 + 10% FBS + 1% PS. BT-549 cells were cultured in 
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RPMI-1640 + 10 µg/mL insulin + 10% FBS + 1% PS. HS-578T cells were 
cultured in DMEM + 10 µg/mL insulin + 10% FBS + 1% PS. BT-20 cells were 
cultured in DMEM + 1x Amino Acids + 10% FBS + 1% PS. MDA-MB-175 cells 
were cultured in DMEM + 10% FBS + 1% PS. MDA-MB-468 cells were cultured 
in DMEM/F12 + 10% FBS + 1% PS. 
 
3.3.3 siRNA Transfection 
 
TNBC cells were transfected with siRNA to NTC, AMPKα1, AMPKα2, 
p110α, p110β, p85α, p85β, Akt1, or Akt2. The final siRNA concentration used in 
each experiment is indicated in the relevant descriptions. The siRNAs were 
mixed with Lipofectamine RNAiMAX in Opti-MEM for 20 min. The ratio of Opti-
MEM to complete medium was 1:4. Medium was changed every 24 h until cell 
lysis or subsequent seeding for downstream applications. 
 
3.3.4 Radiation Treatment 
 
(I) In time-course and dose-response experiments, MDA-MB-231 cells 
were irradiated at the indicated doses with an X-RAD 225XL (Precision X-Ray, 
North Branford, CT) at the X-ray Service Center of the Department of Toxicology 
& Cancer Biology. The X-ray beam setting was 225 kVp with 0.3 mm Cu filtration. 
The beam output was calibrated following AAPM TG-61 protocol with 
measurement done in-air. An A1SL ion chamber (Standard Imaging, Madision, 
WI) was used which is calibrated at the University of Wisconsin Accredited 
Dosimetry Calibration Laboratory (UW ADCL) in terms of air kerma (Gy/C). 
Accurate absorbed doses to water were calculated by considering the impact of 
backscattering as previously described [117]. Cells were lysed for 
immunoblotting at the indicated times. (II) To establish radiation-induced 
apoptosis induction, two methods were used. The first was a single radiation 
dose (0, 6, or 10 Gy) followed by incubation at 37°C and 5% CO2 for 48 h or 72 h 
before lysis. The second was a fractionated approach in which cells were 
irradiated at the same dose (0, 2, 4, or 6 Gy) daily for 4 d with lysis occurring 24 
h after the last dose. (III) MDA-MB-231 cells were transfected with siRNA to 
NTC, AMPKα1, Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1) 
individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM total), and 
(3) siNTC: 100 nM. Cells were irradiated at the indicated doses either on the 
same day as transfection or 24 h after transfection. Cells were incubated at 37°C 
and 5% CO2 for 72 h after transfection before lysis for immunoblotting. 
 
3.3.5 Analysis of Glycolytic Rate 
 
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1, 
or AMPKα2. Medium was changed after 24 h, and cells were seeded into 
Seahorse XF96 Cell Culture Microplates at a density of 20,000 cells per well after 
48 h. At 72 h post transfection, the Redox Metabolism Shared Resource Facility 
at the University of Kentucky measured the glycolytic rate with a Seahorse 
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XFe96 Analyzer (Agilent, Santa Clara, CA). The Glycolytic Rate Assay was 
conducted according to the manufacturer’s protocol [118]. Cells were initially 
treated with 0.5 μM rotenone and 0.5 μM antimycin A before a final injection of 
50 mM 2-deoxy-D-glucose. Analysis was performed with the Agilent Seahorse 
Wave Desktop software. Measurements of the glycolytic rate were based on the 
Glycolytic Proton Efflux Rate (glycoPER). The buffer factor was set to 2.4 
mmol/L/pH, and data were normalized to μg protein in each well. 
 
3.3.6 Immunoblotting 
 
TNBC cells were seeded and transfected as described above. Final 
concentrations were 50 nM or 100 nM, as indicated in the appropriate figures. 
After 72 h, medium was removed, and cells were washed with ice cold 1x PBS. 
Cells were then scraped and lysed in 1x radioimmunoprecipitation assay (RIPA) 
buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were 
incubated on ice for 20 min with 10-sec vortexes every 5 min before 
centrifugation at 14,000 rpm for 20 min at 4°C. Protein concentrations in the 
lysates were then determined. Equal amounts of protein were reduced and 
denatured by heating at 80°C for 10 min before being resolved on 4-12% Bis-Tris 
gels. The proteins were then transferred to polyvinylidene fluoride (PVDF) 
membranes, blocked with 10% milk for at least 1 h, and incubated in primary 
antibody solutions overnight at 4°C. On the next day, the membranes were 
washed twice with 1x Tris-buffered saline with Tween 20 (TBST) for 5 min and 10 
min before incubation with secondary antibody solutions (1:10,000 dilutions) for 1 
h at room temperature. The membranes were then washed twice with TBST for 
15 min and 20 min before Amersham ECL or Immobilon were added to the 
membranes for protein detection. Stripping buffer was used on membranes 
where required. 
 
To determine apoptosis induction after radiation, the above procedure was 
modified. First, to include floating cells that had undergone apoptosis, the 
medium at 48 h post transfection was saved and frozen at 80°C until cell lysis. At 
the time of lysis, cells were scraped before medium removal, combined with the 
previously frozen medium, and centrifuged at 14,000 rpm for 5 min at 4°C. The 
medium was then suctioned off, and the remaining pellet was washed with 1x 
PBS and centrifuged at 14,000 rpm for 5 min at 4°C. After removing the PBS, the 
cells were lysed with 1x RIPA buffer containing 1 mM PMSF as described above. 
 
3.3.7 Cell Counting Assay 
 
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1, 
or AMPKα2 as described above. Medium was changed after 24 h. After 48 h, 
cells were washed with 1x PBS, trypsinized, and counted with a Beckman 
Coulter Vi-Cell XR. Then equal numbers of each transfected cell (0.1 x 106 cells 
per well) were seeded in 6-well plates and incubated under normal cell culture 
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conditions. Medium was changed after 72 h, and cell counting was performed 
after 96 h with the same instrument. 
 
3.3.8 Sulforhodamine B (SRB) Assay 
 
MDA-MB-231 cells were transfected with siRNA to NTC, AMPKα1, 
AMPKα2, Akt1, or p110α (including combinations). Transfection concentrations 
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM 
total), and (3) siNTC: 100 nM. Medium was changed after 24 h, and equal 
numbers of each transfected cell (3,000 cells per well) were seeded in 96-well 
plates after 48 h. Cells were allowed to incubate under normal cell culture 
conditions for 48 h. Cells were then fixed, stained, and quantified following the 
CytoscanTM SRB Cell Cytotoxicity Assay protocol. 
 
3.3.9 Colony Formation Assay 
 
MDA-MB-231 cells were transfected with siRNA to NTC, AMPKα1, Akt1, 
or AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA: 50 nM, 
(2) combination siRNA: 50 nM each (100 nM total), and (3) siNTC: 100 nM. After 
48 h, cells were seeded at equal density in 96-well plates (100 cells/well). Cells 
were then exposed to radiation (0 or 4 Gy) on the following day. After 7 days, 
cells were fixed, stained, and quantified following the SRB Assay protocol 
described above. 
 
3.3.10 Flow Cytometry 
 
MDA-MB-231 cells were transfected with 50 nM siRNA to NTC, AMPKα1, 
or AMPKα2 as described above. Medium was changed after 24 h, and cells were 
seeded into separate 10-cm plates after 48 h. On the following day, cells were 
collected, fixed in 66% ethanol, and stored at 4°C for at least 2 h. Before 
analysis, cells were rehydrated in PBS and stained with a solution containing 
propidium iodide and RNase for 30 min at 37°C in the dark. Analysis of DNA 
content was performed by measuring the propidium iodide fluorescence intensity 
with a flow cytometer in the Flow Cytometry and Immune Monitoring Core at the 
University of Kentucky. 
 
3.3.11 Immunohistochemistry 
 
TNBC whole tissue samples were selected by the Markey Cancer Center 
Biospecimen Core. 4-μm slides were deparaffinized and hydrated stepwise. 
Antigen retrieval was carried out in a Biocare Medical decloaking chamber at 
95°C for 20 min, followed by quenching of endogenous peroxidase activity and 
incubation with primary antibody overnight at 4°C. The slides were subsequently 
incubated with Vector Laboratories ImmPRESS® anti-rabbit HRP polymer for 30 
min at room temperature and staining was visualized with DAB (Dako). Antibody 
specific conditions were as follows: (1) AMPKα1: Dako high pH antigen retrieval 
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buffer; 10-min DAB incubation; 1:175 dilution and (2) AMPKα2: Dako low pH 
antigen retrieval buffer; 5-min DAB incubation; 1:300 dilution. A pathologist who 
was blinded to the stage of disease scored the samples for staining intensity and 
distribution percentage on scales of 0-3. For staining intensity: 0 = negative; 1 = 
weak; 2 = moderate; and 3 = strong. For distribution percentage: 0 = 0%; 1 = 1-
10%; 2 = 11-50%; and 3 = 51-100%. 
 
TNBC patient-derived xenografts (PDXs) were from Dr. Kathleen 
O’Connor’s laboratory and were immunostained as described above except the 
AMPKα1 dilution was 1:100 and the AMPKα2 dilution was 1:200. 
 
3.3.12 Statistical Analysis 
 
Descriptive statistics including means and standard deviations (SD) are 
presented in each experimental group and displayed in bar graphs. Comparisons 
of WB, proliferation, oxidative stress markers, and SRB absorbance were 
performed using the one sample t-test, one way and two-way analysis of 
variance (ANOVA) with Holm's adjustment for multiple testing between groups. 
For the combination studies, a two-way ANOVA with factors for 
AMPKα1/AMPKα2 knockdown and Akt1 or p110α treatments along with 
interaction between factors was used. Likewise, two-way ANOVA with an 
interaction term was utilized to account for the differential effect of radiation in the 
comparison of AMPKα1/AMPKα2 knockdown and Akt1 single and combination 
groups. p<0.05 was considered to indicate a statistically significant difference. 
Statistical analyses were performed using SAS software version 9.4 (SAS Inc., 
Cary, NC, USA). 
 
3.4 Results 
 
3.4.1 Analysis of AMPKα1 and AMPKα2 expression in TNBC patient samples, 
cell lines, and PDXs 
 
AMPK is an important regulator of cellular metabolism that has recently 
gained attention as a potential target in cancer therapy. The catalytic subunit is 
composed of α1 and α2 isoforms; expression of the individual isoforms has not 
been studied in TNBC. Therefore, we initially examined expression of AMPKα1 
and AMPKα2 isoforms in TNBC patient samples, cell lines, and PDXs. 
Representative IHC staining of both AMPKα1 and AMPKα2 in patient samples is 
shown in Figure 3.1A. In these images, AMPKα1 was expressed in the cytoplasm 
while AMPKα2 was expressed in both the nucleus and cytoplasm. Figure 3.1B 
indicates the scoring distribution of AMPKα1 and AMPKα2 among the patient 
samples. Each sample received a score of 4, 5, or 6 for both AMPKα1 and 
AMPKα2, indicating strong and/or widespread expression in each tumor. Next, 
cellular localization of AMPKα1 and AMPKα2 was compared in these patient 
samples. As shown in Figure 3.1C, AMPKα1 was expressed only in the 
cytoplasm, while AMPKα2 was found in both the cytoplasm and the nucleus. 
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Immunoblotting was then used to study the expression of both isoforms in a 
panel of TNBC cell lines (Figure 3.1D). AMPKα1 was expressed in all cell lines 
with the lowest level in MDA-MB-453 cells, but AMPKα2 expression was more 
variable. MDA-MB-231, MDA-MB-453, MDA-MB-468, BT-20, and MDA-MB-175 
cells had high AMPKα2 expression, while BT-549, HS-578T, HCC-1806, and 
HCC-1143 cells had low AMPKα2 expression. 
 
We extended our analysis to include AMPKα1 and AMPKα2 expression in 
TNBC PDX samples. Representative IHC staining of AMPKα1 and AMPKα2 in 
TNBC PDX samples is shown in Figure 3.2A. In these images, AMPKα1 was 
expressed in the cytoplasm while AMPKα2 was found in both the nucleus and 
cytoplasm. The scoring distribution of AMPKα1 and AMPKα2 in the PDX 
samples is indicated in Figure 3.2B. All samples were scored as 4, 5, or 6, 
signifying strong and/or widespread expression. Analysis of isoform localization 
was also done. As shown in Figure 3.2C, AMPKα1 was found only in the 
cytoplasm, while AMPKα2 was expressed in both the nucleus and the cytoplasm. 
Taken together, our results indicate that AMPKα1 and AMPKα2 are widely 
expressed in TNBC with AMPKα2 predominantly localized to the nucleus. 
 
3.4.2 AMPKα1 and AMPKα2 promote TNBC proliferation and cell cycle 
progression 
 
The individual roles of AMPKα1 and AMPKα2 isoforms in TNBC are not 
well understood. Therefore, we examined how each isoform impacts proliferation 
and metabolism in TNBC cells. Using siRNA transfection, levels of both AMPKα1 
and AMPKα2 were successfully reduced after 72 h in MDA-MB-231, MDA-MB-
468, and BT-20 cells (Figure 3.3A). Knockdown of either isoform led to 
decreased cyclin D1 levels in MDA-MB-231 and MDA-MB-468 cells, while only 
AMPKα1 knockdown resulted in cyclin D1 suppression in BT-20 cells. 
Densitometry analysis indicated statistically significant reductions in cyclin D1 
with AMPKα1 knockdown in all 3 cell lines and with AMPKα2 knockdown in 
MDA-MB-231 and MDA-MB-468 cells (Figure 3.4A). 
 
We next determined whether AMPKα regulates cell cycle and proliferation 
in MDA-MB-231 cells. Flow cytometry analysis established that knockdown of 
either AMPKα1 or AMPKα2 led to G1 cell cycle arrest (Figure 3.3B). The tumor 
suppressor p53 can prevent cells from progressing past G1, and knockdown of 
either AMPKα1 or AMPKα2 led to increased expression of p53 (Figure 3.3C). 
Densitometry analysis indicated that the increases in p53 were statistically 
significant (Figure 3.4B). To evaluate whether the induced G1 cell cycle arrest 
impacted MDA-MB-231 growth, a proliferation assay was then done. As shown in 
Fig 2D, knockdown of either AMPKα1 or AMPKα2 resulted in statistically 
significant decreases in MDA-MB-231 proliferation. 
 
Glycolytic activity increases during the G1 phase, and AMPK has been 
shown to affect the cellular glycolytic rate [60, 62, 119]. Therefore, the effect that 
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AMPKα1 or AMPKα2 knockdown has on glycolysis in MDA-MB-231 cells was 
determined. Figure 3.3E indicates that knockdown of AMPKα1—but not 
AMPKα2—decreased the glycolytic rate in MDA-MB-231 cells. The decreases in 
glycolytic flux with AMPKα1 knockdown were statistically significant for both 
basal and compensatory glycolysis (Figures 3.5A and 3.5B). Taken together, our 
results indicate that both AMPKα1 and AMPKα2 promote cell cycle progression 
and proliferation of MDA-MB-231 cells by potentially downregulating p53 
expression while AMPKα1 also facilitates glycolytic flux. 
 
3.4.3 Knockdown of Akt1 or p110α induces apoptosis and reduces proliferation in 
MDA-MB-231 cells 
 
The impact of individual PI3K subunits or Akt isoforms on TNBC 
proliferation or apoptosis has not been studied. The effect of combined inhibition 
of PI3K and AMPKα on TNBC growth and survival is also unknown. Therefore, 
we examined how knockdown of PI3K signaling components—alone or in 
combination with AMPKα isoforms—affected apoptosis induction and 
proliferation in MDA-MB-231 cells. Initially, siRNA was used to establish 
knockdown of p110α, p110β, p85α, p85β, Akt1, and Akt2. Figures 3.6A and 3.6B 
shows siRNA knockdown of all components at 72 h and 96 h, respectively. 
Knockdown of all proteins except p85β was accomplished at 72 h (Figure 3.6A), 
while knockdown of p85β was confirmed at 96 h (Figure 3.6B). At both 72 h and 
96 h, suppression of Akt1 and p110α led to the largest decreases in cyclin D1 
and the most substantial increases in cleaved PARP. 
 
Next, the effect of combined knockdown of PI3K and AMPKα on apoptosis 
induction and proliferation in MDA-MB-231 cells was determined. As shown in 
Figure 3.6C, PARP cleavage is induced with Akt1 knockdown alone or in 
combination with knockdown of AMPKα1 or AMPKα2 in MDA-MB-231 cells. 
Slight increases in PARP cleavage were also found with knockdown of p110α by 
itself or when combined with knockdown of AMPKα2. In addition, an SRB growth 
assay was performed to establish whether combined knockdown of AMPKα 
isoforms with Akt1 or p110α suppressed MDA-MB-231 proliferation more than 
knockdown of each protein alone. Single knockdown of AMPKα1, AMPKα2, Akt1, 
or p110α significantly reduced MDA-MB-231 growth (Figure 3.6D). Additionally, 
MDA-MB-231 proliferation was further decreased when knockdown of AMPKα1 
was combined with knockdown of either Akt1 or p110α. However, the growth of 
MDA-MB-231 cells was not further suppressed when AMPKα2 knockdown was 
combined with knockdown of either Akt1 or p110α. Taken together, our results 
indicate that silencing either Akt1 or p110α induces apoptosis and suppresses 
proliferation of MDA-MB-231 cells—and combination knockdown with AMPKα1 
further reduces growth. 
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3.4.4 Radiotherapy increases activated and total AMPKα in MDA-MB-231 cells 
 
AMPK has been activated in cancer cells by radiation and has increased 
survival through the autophagy pathway [80, 84, 85]. However, the ability of 
radiotherapy to activate AMPK in TNBC in unknown. Therefore, we established 
whether radiation leads to AMPKα activation in MDA-MB-231 cells. Figure 3.7A 
indicates that AMPKα was activated 1 h after exposure to increasing doses of 
radiation (4, 6, and 8 Gy). AMPKα was activated to a similar degree at each 
dose, indicating that the effect was not dose-dependent. In addition, levels of 
total AMPKα were increased at every dosage. DNA-dependent protein kinase 
(DNA-PK) is a DNA repair enzyme that was also activated at each radiation 
dose. Figure 3.7B shows that 6 Gy radiation activated AMPK in MDA-MB-231 
cells 1 h and 2 h post exposure—with the largest increase at 1 h. However, 
pAMPK levels returned to baseline at 4 h and were not elevated at 24 h. Total 
AMPKα was also slightly increased 1 h and 2 h after radiation treatment. DNA-
PK phosphorylation was detected after 1 h and decreased in a stepwise fashion 
at 2 h, 4 h, and 24 h post exposure. Taken together, our results indicate that 
radiation increases activated and total levels of AMPKα in a non-dose-dependent 
manner in MDA-MB-231 cells. 
 
3.4.5 Akt1 knockdown potentiates radiation-induced apoptosis and further 
suppresses survival after radiation in MDA-MB-231 cells 
 
Radiotherapy causes DNA damage, stress, and apoptosis. However, 
activation of AMPK and Akt may help cells adapt to—and eventually overcome—
these stressful conditions. Therefore, we evaluated how knockdown of AMPKα1 
and Akt1—alone or in combination—impacts radiation-induced apoptosis in 
MDA-MB-231 cells. Attempts were initially made to determine when apoptosis is 
induced in MDA-MB-231 cells following radiotherapy. Two approaches were 
used: (1) a single dose of radiation followed by lysis after 48 h or 72 h or (2) a 
fractionated approach in which cells were radiated at the same dose for 4 
consecutive days and harvested 24 h after the last treatment (96 h after the first 
dose). As shown in Figure 3.8A, a single dose of 6 or 10 Gy induced cleavage of 
PARP and caspase-3 after 72 h in MDA-MB-231 cells. In addition, a single dose 
of 10 Gy slightly induced PARP cleavage after 48 h. In Figure 3.8B, fractionated 
dosing (2, 4, or 6 Gy daily for 4 d) also led to strong PARP and caspase-3 
cleavage after 96 h total in MDA-MB-231 cells. 
 
To determine whether combined knockdown of AMPKα1 and Akt1 
potentiates radiation-induced apoptosis, a single radiation dosing scheme similar 
to that in Figure 3.8A was used instead of the fractionated approach. Figure 3.8C 
indicates that 6 Gy radiation induced PARP cleavage after 48 h and that this was 
substantially enhanced when combined with 72 h Akt1 knockdown. However, 
knockdown of AMPKα1 alone or in combination with Akt1 did not enhance this 
effect. These findings were verified in Figure 3.9A. As shown in Fig 5D, similar 
results were observed when radiating with 4 Gy and incubating for 72 h. PARP 
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cleavage was induced with 4 Gy radiation alone after 72 h but was enhanced 
when radiation was combined with 72 h Akt1 knockdown. As with the 48 h 
timepoint, AMPKα1 knockdown alone or in combination with Akt1 did not 
potentiate the increases in PARP cleavage. The effect of Akt1 silencing on MDA-
MB-231 survival after radiation was also examined. Either Akt1 knockdown or 
treatment with 4 Gy radiation significantly reduced colony formation of MDA-MB-
231 cells, and survival was further suppressed in radiated cells with Akt1 
knockdown (Figure 3.9B). Knockdown of AMPKα1 slightly attenuated the effect 
of Akt1 knockdown at both 0 Gy and 4 Gy. Taken together, our results indicate 
that silencing Akt1 sensitizes MDA-MB-231 cells to radiation-induced apoptosis 
and decreases survival after radiotherapy. 
 
3.4.6 MK-2206 treatment enhances radiation-induced apoptosis in MDA-MB-231 
cells 
 
To increase the clinical relevance of our findings, we examined the effect 
of Akt inhibitors MK-2206, A-674563, AZD5363 and Perifosine on apoptosis 
induction in MDA-MB-231 cells after radiation. Cells were treated with Akt 
inhibitors 48 h after radiation exposure (Figures 3.8E and 3.8F). Treatment with 
MK-2206 alone for 24 h reduced Akt1 expression and induced PARP cleavage in 
MDA-MB-231 cells. In cells that were exposed to 4 Gy radiation, treatment with 
MK-2206 synergistically increased PARP cleavage compared to either modality 
alone. Administration of Perifosine also reduced Akt1 expression but did not 
synergistically increase radiation-induced apoptosis. Treatment with other Akt 
inhibitors—A-674563 or AZD5363—did not reduce Akt1 levels or induce 
apoptosis. Taken together, our results indicate that reducing Akt1 expression 
with MK-2206 at the initiation of apoptosis can potentiate the effect of 
radiotherapy. Targeting Akt1 expression as a radiosensitizer in TNBC could 
enhance patient outcomes and mitigate toxicity associated with both PI3K 
pathway inhibition and radiotherapy. 
 
3.5 Discussion 
 
Triple-negative breast cancer (TNBC) (estrogen receptor-negative, 
progesterone receptor-negative, and HER2-negative) is an aggressive subgroup 
of breast cancer [3, 4]. Treating patients with TNBC remains clinically 
challenging; radiation therapy is able to improve locoregional control in breast 
cancer patients both after breast conserving surgery or mastectomy, with positive 
impact on long-term survival [33, 34]. Radiotherapy’s importance as a treatment 
modality in TNBC prompted our interest in attempting to further increase survival 
advantage of radiotherapy in TNBC patients. We targeted two important cellular 
pathways, AMPK and PI3K/Akt, with the hypothesis that their combined inhibition 
would potentiate radiation-induced apoptosis.  
 
The expression and function of individual AMPKα isoforms in TNBC has 
not previously been studied. We demonstrated that both AMPKα1 and AMPKα2 
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were expressed in TNBC patient samples, cell lines, and PDXs. AMPKα1 was 
localized to the cytoplasm, while AMPKα2 was expressed in both the cytoplasm 
and the nucleus. AMPKα2 expression has been shown to be enriched in the 
nucleus compared to AMPKα1 in rat insulinoma cells [120]. AMPKα controls 
cellular proliferation and glycolytic flux in TNBC [60, 62], but distinctions have not 
been made between the two isoforms. We found that both AMPKα1 and 
AMPKα2 promote proliferation and cell cycle progression of MDA-MB-231 cells. 
We also determined that knockdown of either AMPKα1 or AMPKα2 led to 
upregulation of p53, a tumor suppressor that can induce cell cycle arrest. 
Although silencing AMPKα2 in BT-20 cells did not reduce cyclin D1 expression, 
we suspect that this may be due to insufficient knockdown. Our densitometry 
calculations indicated a trend toward reduced cyclin D1 expression in BT-20 cells 
with AMPKα2 knockdown, and we expect that a more robust knockdown would 
yield results consistent with our other cell lines. Taken together, our results 
suggest that AMPKα1 and AMPKα2 support proliferation of MDA-MB-231 cells 
by potentially reducing p53 levels. In other cancer cells, increased AMPK activity 
or expression has led to amplified p53 levels [63, 121]. AMPK has a complex 
cellular role that can vary based on the method by which AMPK is manipulated. 
For instance, TNBC growth can be suppressed by AMPK activation or with stable 
AMPKα knockdown [62, 67]. Therefore, we attribute the difference in our findings 
to using a knockdown model instead of drug-induced AMPK activation or 
overexpression. To our knowledge, no studies have established a link between 
knockdown of endogenous AMPKα expression and p53 levels in cancer cells. 
Further work is needed to establish the mechanism by which AMPKα1 or 
AMPKα2 regulates p53 expression in TNBC cells. Knockdown of AMPKα1 did 
not enhance radiation-induced apoptosis, suggesting that inhibiting the AMPKα 
pathway does not provide further benefit. However, there may be value in 
examining the combination of AMPKα activation and radiation in TNBC. Other 
studies have demonstrated an advantage of AMPKα activation during 
radiotherapy [45, 79, 82, 83]. In particular, metformin—an AMPKα activator—has 
been shown to increase cell death after radiation exposure in lung, esophageal, 
and estrogen receptor-positive breast cancer cells [79, 82, 83]. This is partly due 
to AMPK’s ability to inhibit mTOR signaling, so a combination approach with Akt1 
knockdown could be examined [45, 82, 83]. Future work could evaluate the 
ability of increased AMPKα activity—whether by genetic upregulation or chemical 
activation—to sensitize TNBC cells to radiation. 
 
The PI3K/Akt/mTOR pathway is altered more frequently than any other 
pathway in breast cancer [96]. However, the effect of individual subunits or 
isoforms on proliferation or apoptosis induction in TNBC is unknown. We found 
that knockdown of either Akt1 or p110α reduced cyclin D1 expression and 
increased cleaved PARP expression in TNBC cells. The other components—
Akt2, p110β, p85α, and p85β—had minimal effects on cyclin D1 expression or 
PARP cleavage. We selected Akt1 as our main target for combination therapy 
with radiation, because its knockdown alone induced a higher rate of apoptosis 
compared to p110α knockdown. Other studies have also found that Akt1 is the 
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most important Akt isoform at inhibiting apoptosis induction in breast cancer and 
mouse myeloid cells [122, 123]. Suppressing Akt1 expression during 
radiotherapy could be a valuable approach in treating TNBC that is refractory to 
neoadjuvant chemotherapy (NAC). TNBC is initially treated with NAC to shrink 
the tumor as much as possible before surgery. Radiotherapy may be initiated 
after surgery in an attempt to induce death of resistant cells. Our data indicate 
that suppressing Akt1 levels—possibly with MK-2206—may sensitize resistant 
TNBC tumors to radiotherapy. To our knowledge, this is the first study to 
establish a link between Akt1 expression and radiation-induced apoptosis in 
TNBC. This strategy could reduce future recurrence and ultimately lead to better 
outcomes for TNBC patients. 
 
Apoptosis is one of the primary methods by which radiotherapy induces 
cell death [114]. We demonstrate that the apoptotic cascade is not immediately 
activated after radiation and it takes up to 48h after radiation therapy to detect 
apoptosis in TNBC cells. Akt inhibition or knockdown right after radiation therapy 
do not synergistically increase the effect of radiation therapy. However, we show 
the potential for the selective sensitization of tumor cells to radiation therapy with 
timed knockdown of Akt1 expression after radiation therapy. MK-2206 promoted 
synergistic apoptosis induction when administered after radiotherapy, and we 
expect drugs that strongly reduce Akt1 expression (similar to genetic knockdown) 
will promote radiation-induced apoptosis to an even greater degree. The ability to 
enhance the effect of radiation therapy by reducing Akt1 levels at the time of 
initial radiation-induced apoptosis induction is a particularly significant finding and 
should be of relevance to the design of clinical combination protocols. By timing 
Akt inhibitor administration with radiation therapy, we can reduce the frequency 
of Akt inhibitor administration and the amount of drug given to the patient with 
TNBC. To our knowledge, this is the first study to identify that an Akt inhibitor can 
be administered in a schedule-dependent manner to induce radiosensitivity in 
TNBC cells. Selective targeting of Akt1 protein expression should also decrease 
the severity of side effects associated with PI3K/Akt pathway inhibition. In 
addition, reducing Akt1 expression to enhance radiotherapy may lessen the 
number of treatments required to induce apoptosis or arrest tumor growth—
potentially making radiation more tolerable for TNBC patients.  
 
In summary (Figure 3.8G), we established that silencing Akt1 sensitized 
TNBC cells to radiation treatment. Knockdown of Akt1 potentiated apoptosis 
induction after radiotherapy and further suppressed TNBC cell survival after 
treatment. Administration of MK-2206 at the initiation of radiation-induced 
apoptosis reduced Akt1 expression and enhanced radiation therapy effect in 
TNBC cells. Importantly, combining radiotherapy with pharmacological inhibition 
of Akt1 expression at the optimal timing is a potentially promising approach for 
the treatment of TNBC that could improve TNBC response to radiotherapy and 
limit toxicity associated with PI3K pathway inhibition. 
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Figure 3.1 Analysis of AMPKα1 and AMPKα2 expression in TNBC whole 
tissue sections and established cell lines. 
(A) Representative IHC staining of AMPKα1 and AMPKα2 in TNBC whole tissue 
sections. (B) Scoring distribution of AMPKα1 and AMPKα2 in TNBC whole tissue 
sections (n = 17). (C) Subcellular localization (nuclear, cytoplasmic, or both) of 
AMPKα1 and AMPKα2 in TNBC whole tissue sections (n = 17). (D) Western blot 
of AMPKα1 and AMPKα2 expression in a panel of established TNBC cell lines (n 
= 9). 
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Figure 3.2 Analysis of AMPKα1 and AMPKα2 expression in TNBC PDX 
samples. 
(A) Representative IHC staining of AMPKα1 and AMPKα2 in TNBC PDX 
samples. (B) Scoring distribution of AMPKα1 and AMPKα2 in TNBC PDX 
samples (n = 7). (C) Subcellular localization (nuclear, cytoplasmic, or both) of 
AMPKα1 and AMPKα2 in TNBC PDX samples (n = 7). 
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Figure 3.3 AMPKα1 and AMPKα2 impact proliferation and cell cycle 
progression in TNBC cells. 
(A) MDA-MB-231, MDA-MB-468, and BT-20 cells were transfected with 50 nM of 
siRNA targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2, and 
cyclin D1 was analyzed by western blot 72h after transfection. (B) MDA-MB-231 
cells were transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2. Cells 
were seeded into 10-cm plates 48h after transfection and collected for cell cycle 
analysis 24h later. (C) MDA-MB-231 cells were transfected with 50 nM of siRNA 
targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2, and p53 was 
analyzed by western blot 72h after transfection. (D) MDA-MB-231 cells were 
transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2. Cells were 
plated at a density of 100,000 cells/well 48h after transfection and counted 96h 
after plating. (E) MDA-MB-231 cells were transfected with 50 nM of siRNA 
targeting AMPKα1 or AMPKα2. Cells were plated at a density of 20,000 cells/well 
48h after transfection, and the glycolytic rate was analyzed 24h later (n = 18). For 
2A-D, the results are representative of 3 independent experiments. For 2E, the 
result is representative of 2 independent experiments. *indicates p-value < 
0.0001. NTC; Non-targeting control was used as a negative control.
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Figure 3.4 Densitometry measurements of cyclin D1 and p53 after AMPKα1 
or AMPKα2 knockdown in TNBC cells. 
(A) MDA-MB-231, MDA-MB-468, and BT-20 cells were transfected with 50 nM of 
siRNA targeting AMPKα1 or AMPKα2. Expression of cyclin D1 was analyzed by 
western blot densitometry 72h after transfection (n = 3). (B) MDA-MB-231 cells 
were transfected with 50 nM of siRNA targeting AMPKα1 or AMPKα2. 
Expression of p53 was analyzed by western blot densitometry 72h after 
transfection (n = 3). *indicates p-value < 0.05; NTC, Non-targeting control was 
used as a negative control. 
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Figure 3.5 Effect of AMPKα1 or AMPKα2 knockdown on basal and 
compensatory glycolysis in MDA-MB-231 cells. 
MDA-MB-231 cells were transfected with 50 nM of siRNA targeting AMPKα1 or 
AMPKα2. Non-targeting control was used as a negative control. Cells were 
seeded at a density of 20,000 cells/well 48h after transfection, and the rates of 
(A) basal and (B) compensatory glycolysis were determined 24h later (n = 18). 
The results are representative of 2 independent experiments. *indicates p-value 
< 0.0001. 
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Figure 3.6 Knockdown of Akt or p110α increases apoptosis and decreases 
proliferation in MDA-MB-231 cells. 
MDA-MB-231 cells were transfected with 100 nM of siRNA to Akt1, Akt2, p110α, 
p110β, p85α, or p85β. Expression of Akt1, Akt2, p110α, p110β, p85α, p85β, 
cyclin D1, and cleaved PARP was determined with western blot (A) 72h and (B) 
96h after transfection. (C) MDA-MB-231 cells were transfected with siRNA to 
AMPKα1, AMPKα2, Akt1, or p110α alone or in combinations. Transfection 
concentrations were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM 
each (100 nM total), and (3) siNTC: 100 nM. Expression of AMPKα1, AMPKα2, 
Akt1, p110α, and cleaved PARP was determined with western blot 72h after 
transfection. (D) MDA-MB-231 cells were transfected with siRNA to AMPKα1, 
AMPKα2, Akt1, or p110α alone or in combinations. Transfection concentrations 
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM 
total), and (3) siNTC: 100 nM. Cells were plated at a density of 3,000 cells/well 
48h after transfection. SRB growth assay was performed 48h after plating (n = 
12). *indicates p-value < 0.0001; NTC, Non-targeting control was used as a 
negative control.
 
 
48 
 
Figure 3.7 Radiation increases levels of activated and total AMPKα in MDA-
MB-231 cells. 
(A) MDA-MB-231 cells were exposed to 0, 2, 4, or 6 Gy radiation dose and 
collected 1h after irradiation. Total and phosphorylated AMPKα and DNA-PKcs 
expression levels were determined by Western blot. (B) MDA-MB-231 cells were 
exposed to 0 or 6 Gy radiation dose and collected 1h, 2h, 4h, or 24h after 
irradiation. Total and phosphorylated AMPKα and DNA-PKcs expression levels 
were determined by Western blot. 
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Figure 3.8 Knockdown of Akt1 potentiates radiation-induced apoptosis in 
MDA-MB-231 cells. 
(A) MDA-MB-231 cells were exposed to 0, 6, or 10 Gy radiation dose and 
collected 48h or 72h after irradiation. Expression of cleaved PARP and cleaved 
caspase-3 was determined by Western blot. (B) MDA-MB-231 cells were 
exposed to 0, 2, 4, or 6 Gy radiation dose daily for 4d and collected 24h after the 
last radiation treatment. Expression of cleaved PARP and cleaved caspase-3 
was determined by Western blot. (C) MDA-MB-231 cells were transfected with 
siRNA to AMPKα1, Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1) 
individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM total), and 
(3) NTC: 100 nM. Cells were exposed to 0 or 6 Gy radiation dose 24h after 
transfection and collected 48h after radiation. Expression of AMPKα1, Akt1, and 
cleaved PARP was determined by Western blot. (D) MDA-MB-231 cells were 
exposed to 0 or 4 Gy radiation dose and then transfected with siRNA to 
AMPKα1, Akt1, or AMPKα1/Akt1 on the same day. Transfection concentrations 
were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM each (100 nM 
total), and (3) NTC: 100 nM. Cells were collected 72h after transfection. 
Expression of AMPKα1, Akt1, and cleaved PARP was determined by Western 
blot. (E) MDA-MB-231 cells were exposed to 0 or 4 Gy radiation dose and then 
incubated for 48h. Cells were then treated with 0 or 10 μM of A-674563 or MK-
2206 for 24h. Expression of pAkt, Akt1, and cleaved PARP was determined by 
western blot. (F) MDA-MB-231 cells were exposed to 0 or 4 Gy radiation dose 
and then incubated for 48h. Cells were then treated with 0 or 10 μM of AZD5363 
or Perifosine for 24h. Expression of pAkt, Akt1, and cleaved PARP was 
determined by western blot. (G) Summary diagram showing Akt1 inhibition and 
radiation-induced apoptosis in TNBC cells. For A-D, NTC (Non-targeting control) 
was used as a negative control. 
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Figure 3.9 Silencing Akt1 enhances radiation-induced apoptosis in MDA-
MB-231 cells. 
(A) MDA-MB-231 cells were transfected with siRNA to AMPKα1, Akt1, or 
AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA: 50 nM, (2) 
combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM. Cells were 
exposed to 0 or 6 Gy radiation dose 24h after transfection and collected 48h after 
radiation. Expression of AMPKα1, Akt1, and cleaved PARP was determined by 
western blot. (B) MDA-MB-231 cells were transfected with siRNA to AMPKα1, 
Akt1, or AMPKα1/Akt1. Transfection concentrations were: (1) individual siRNA: 
50 nM, (2) combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM. 
Cells were seeded at a density of 100 cells/well into 96-well plates 48h after 
transfection. Cells were exposed to 0 or 4 Gy radiation dose 24h later. Colonies 
were fixed and quantified with the SRB assay protocol 1 week after irradiation (n 
= 18). NTC, Non-targeting control was used as a negative control. *indicates p < 
0.01 vs. group control; † indicates p < 0.0001 vs. no radiation. 
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CHAPTER 4: ROLE OF AKT AND AMPK IN TRIPLE NEGATIVE BREAST 
CANCER LUNG METASTASIS 
 
4.1 Abstract 
 
Triple negative breast cancer (TNBC) is a very aggressive disease with a 
5-year relative survival rate of 11% after distant metastasis. Organ metastasis 
imposes stressful conditions on cells, which adapt by increasing energy 
production and upregulating survival pathways. AMP-activated protein kinase 
(AMPK) and Akt control energy levels and survival; however, their role during 
early-stage metastasis is unknown. The purpose of this study was to establish 
whether targeting both Akt and AMPKα in circulating cancer cells suppresses 
TNBC early-stage lung colonization. Silencing Akt1 or Akt2 dramatically 
decreased lung metastasis establishment in lungs by inducing apoptosis or 
inhibiting invasion, respectively. Allosteric inhibition of Akt activity with MK-2206 
did not reduce TNBC lung metastasis. Knockdown of AMPKα1, AMPKα2, or 
AMPKα1/2 did not suppress metastatic colonization of lungs. Taken together, 
these findings demonstrate that metabolic pathways regulated by AMPK isoforms 
are not essential for circulating TNBC tumor cells survival or metastatic lung 
colonization. However, we identify Akt1 or Akt2 expression as key mediators of 
lung colonization that may serve as potential targets to prevent metastatic spread 
and improve survival among TNBC patients. 
 
4.2 Introduction 
 
Breast cancer is the second leading cause of cancer death among women 
globally, and projections estimate that there will be over 42,000 deaths in the 
United States in 2020 [1]. Most deaths are due to metastatic spread of the cancer 
to the lungs, brain, or bone [2]. Triple negative breast cancer (TNBC) is an 
aggressive subtype of breast cancer that comprises 15-20% of overall cases [3-
5, 7, 9]. TNBC, characterized by a lack of expression of the estrogen and 
progesterone receptors and no overexpression of the HER2 protein, consists of a 
diverse group of tumors that affect younger women and are found with greater 
frequency in African Americans [6, 7, 9, 124]. TNBC has proven resistant to 
targeted therapy and is more likely to recur and metastasize to distant organs [6, 
7, 9, 124]. The lungs are the primary site of TNBC colonization with 
approximately 40% of TNBC metastases occurring in the lungs [125]. The 
survival rate for TNBC significantly decreases once it has metastasized to 
systemic organs [37]. The 5-year relative survival rate of localized TNBC is 91% 
and 65% with regional metastasis; however, survival precipitously drops to 11% 
with distant spread [37]. TNBC patients with lung metastases have a median 
survival of only 15 months [126]. Understanding the mechanism of TNBC 
metastatic spread to lungs and preventing the establishment of micrometastases 
in distant organs will directly improve patient survival. 
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Metastasis is a multistep process that requires cells to follow five 
sequential steps: infiltrate surrounding tissue, intravasate into a blood or 
lymphatic vessel, survive during transit, extravasate into an organ, and proliferate 
to form colonies [127]. Cells must become motile before infiltrating surrounding 
tissue, and they undergo the epithelial-to-mesenchymal transition (EMT) to 
increase migratory ability [127]. Once in a vessel, cells travel and must survive 
until they lodge in capillaries or adhere to endothelial cells of the vessel wall 
[128]. Cells then extravasate into surrounding tissue within a few hours [128]. 
After arriving at a distant site, metastatic cells rely on oncogenes to promote 
survival [128]. Only a subset of surviving cells proliferates to form a colony [128]. 
Metastasis is extremely inefficient with less than 0.1% of cells surviving at distant 
sites [127]. Survival during transport and extravasation into an organ are key 
steps in early-stage metastasis that can be targeted to prevent the establishment 
of colonies at distant sites. Since metastasis to distant organs happens in a 
short-time frame, we decided to identify the role of key survival or metabolism 
proteins by regulating their expression in circulating cancer cells. This model 
focuses specifically on the fate of cancer cells after intravasation but before 
proliferation of micrometastases. 
 
During organ metastasis, cells rely on increased energy production and 
oncogene expression to adapt to stressful conditions [128, 129]. Inhibiting 
pathways that help cells alter metabolism or overcome stresses during early-
stage metastasis may reduce their ability to successfully metastasize. Akt and 
AMP-activated protein kinase (AMPK) are two proteins that play crucial roles in 
cellular survival and metabolism, respectively. Moreover, Akt and AMPK 
reciprocally regulate each other during matrix attachment and detachment in 
breast cancer [115]. Akt promotes growth of matrix-attached cells, while AMPK 
increases energy availability for matrix-detached cells [115]. Concurrently 
targeting signaling through Akt and AMPK may synergistically reduce the ability 
of TNBC to metastasize. 
 
Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is 
composed of three isoforms: Akt1, Akt2, and Akt3 [92-95, 116, 130]. Akt 
promotes cellular growth and survival by phosphorylating and regulating many 
targets, including the mammalian target of rapamycin (mTOR) [92-95, 116, 130]. 
The ability of Akt1 and Akt2 to control metastasis of estrogen receptor-positive 
(ER+) and HER2-amplied breast cancers has previously been studied. Akt1 
inhibits metastasis of both breast cancer subtypes, while Akt2 has a pro-
metastatic role in both cases [104-106]. However, the impact of Akt1 and Akt2 on 
TNBC metastasis is unknown. AMPK is a heterotrimeric complex that is 
composed of an α catalytic subunit and β and γ regulatory subunits [44, 46-48, 
53]. The catalytic domain is comprised of α1 and α2 isoforms [44, 46-48, 53]. 
AMPK is a major metabolic regulator that maintains energy homeostasis of cells 
by increasing ATP production and reducing ATP consumption [44, 46-48, 53]. In 
particular, AMPK reduces lipid synthesis and stimulates fatty acid oxidation by 
phosphorylating acetyl CoA carboxylase [44, 47, 48, 53]. Both fatty acid 
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synthesis and oxidation can promote metastasis [89]. AMPK may play a key role 
in balancing flux through these pathways during different stages of metastasis. 
However, the specific steps of TNBC metastasis that are regulated by AMPKα1 
and AMPKα2 is unclear. Moreover, combined targeting of individual Akt and 
AMPKα isoforms to reduce TNBC metastasis has not been previously examined. 
 
Here, we determined how Akt and AMPKα isoforms affect the early-stage 
metastatic potential of TNBC cells and whether combined inhibition can 
synergistically block metastasis in vivo. We found that silencing either Akt1 or 
Akt2 dramatically decreased lung colonization of TNBC cells by inducing 
apoptosis or inhibiting invasion, respectively. The reductions in metastasis were 
independent of Akt activation. Knockdown of AMPKα1, AMPKα2, or AMPKα1/2 
did not prevent lung metastasis or synergistically suppress lung colonization 
when combined with Akt isoform knockdown. Taken together, our findings 
establish Akt1 and Akt2 as key mediators of TNBC lung colonization. 
Suppressing Akt1 or Akt2 expression may directly decrease mortality in TNBC 
patients. 
 
4.3 Materials and methods 
 
4.3.1 Materials 
 
Roswell Park Memorial Institute (RPMI) 1640 medium was from Thermo 
Fisher (Waltham, MA). DMEM/F12 was from Sigma-Aldrich (St. Louis, MO). Fetal 
bovine serum (FBS), 100x penicillin-streptomycin solution (PS), and Dulbecco’s 
Phosphate Buffered Saline (PBS) were from Sigma-Aldrich. Opti-MEM and 
Lipofectamine RNAiMAX were from Thermo Fisher. Protein Assay Dye was from 
Bio-Rad (Hercules, CA). Amersham ECL Prime Western Blotting Detection 
Reagent was from GE Healthcare Life Sciences (Chicago, IL). Immobilon 
Western Chemiluminescent HRP Substrate was from Millipore (Burlington, MA). 
Pooled siRNAs for AMPKα1, AMPKα2, and AMPKα1/2 were from Santa Cruz 
Biotechnology (Dallas, TX). Pooled siRNAs for Akt1 and Akt2 were from Thermo 
Fisher. MISSION pLKO.1-puro-CMV-TurboGFP Positive Control Transduction 
Particles (Sigma-Millipore; #SHC003V) were used to establish MDA-MB-231 
green fluorescent protein (GFP) cells. MK-2206 2HCl was from Cayman 
Chemical (Ann Arbor, MI). Primary antibodies used in this study include: Abcam: 
(1) AMPKα1, ab32047 (1:1000 for WB and 1:250 for IHC) and (2) AMPKα2, 
ab3760 (1:1000 for WB and 1:500 for IHC); Cell Signaling Technology (Danvers, 
MA): (1) pAkt, #4060 (1:2000 for WB), (2) Akt1, #75692 (1:1000 for WB), (3) 
Akt2, #3063 (1:1000 for WB), (4) Cleaved PARP, #5625 (1:1000 for WB), (5) ZO-
1, #8193 (1:1000 for WB), (6) ZEB1, #3396 (1:1000 for WB), (7) Claudin-1, 
#13255 (1:1000 for WB), (8) E-cadherin, #3195 (1:1000 for WB), (9) Vimentin, 
#5741 (1:1000 for WB), (10) β-catenin, #8480 (1:1000 for WB), (11) Snail, #3879 
(1:1000 for WB), (12) Bcl-2, #4223 (1:1000 for WB), (13) Bcl-xL, #2764 (1:1000 
for WB), (14) Mcl-1, #5453 (1:1000 for WB), (15) Bim, #2933 (1:1000 for WB), 
(16) Bad, #9239 (1:1000 for WB), and (17) BID, #2202 (1:1000 for WB); and 
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Sigma-Aldrich: β-actin (1:10,000 for WB). Akt1, #sc-5298 (1:500 for IHC), Akt2, 
#sc-5270 (1:500 for IHC), and secondary antibodies were from Santa Cruz 
Biotechnology. 
 
4.3.2 Cell Culture 
 
TNBC cells (MDA-MB-231 and MDA-MB-468 cells) were from the 
American Type Culture Collection and cultured in a humidified incubator at 37°C 
and 5% CO2. MDA-MB-231 cells were cultured in RPMI + 10% FBS + 1% PS. 
MDA-MB-468 cells were cultured in DMEM/F12 + 10% FBS + 1% PS. To 
generate MDA-MB-231 GFP cell line, 5,000 cells were seeded into a 96-well 
plate and incubated at standard cell culture conditions overnight. On the following 
day, cells were transfected with GFP lentiviral particles (MOI = 40) in medium 
supplemented with 10 μg/ml polybrene. The medium was changed after 24h, and 
cells were seeded 24h later into a 24-well plate. The cells were selected the next 
day with 1 μg/mL of puromycin. 
 
4.3.3 siRNA Transfection 
 
TNBC cells were transfected with 50 nM of siRNA to NTC, Akt1, Akt2, 
AMPKα1, AMPKα2, or AMPKα1/2. The siRNAs were mixed with Lipofectamine 
RNAiMAX in Opti-MEM for 20 min. The ratio of Opti-MEM to complete medium 
was 1:4. Medium was changed every 24h until cells were injected into mice or 
lysed for western blotting. 
 
4.3.4 Western blotting 
 
TNBC cells were seeded and then transfected as described above. 
Medium was changed after 24h and again after 48h. After incubation for a total of 
72h, medium was removed, and cells were washed with ice cold 1x PBS. Cells 
were then scraped and lysed in 1x radioimmunoprecipitation assay (RIPA) buffer 
containing 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were incubated on 
ice for 20 min with 10-sec vortexes every 5 min before centrifugation at 14,000 
rpm for 20 min at 4°C. Protein concentrations in the lysates were then 
determined. Equal amounts of protein were reduced and denatured by heating at 
80°C for 10 min before being resolved on 4-12% Bis-Tris gels. The proteins were 
then transferred to polyvinylidene fluoride (PVDF) membranes, blocked with 10% 
milk for at least 1h, and incubated in primary antibody solutions overnight at 4°C. 
On the next day, the membranes were washed twice with 1x Tris-buffered saline 
with Tween 20 (TBST) for 5 min and 10 min before incubation with secondary 
antibody solutions (1:10,000 dilutions) for 1h at room temperature. The 
membranes were then washed twice with TBST for 15 min and 20 min before 
Amersham ECL or Immobilon was added to the membranes for protein detection. 
Stripping buffer was used on membranes where required. 
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4.3.5 Immunohistochemistry 
 
Samples of TNBC lymph node metastases were identified by the Markey 
Cancer Center Biospecimen Procurement and Translational Pathology shared 
resource facility. Immunohistochemistry (IHC) was performed as previously 
described [131]. Briefly, slides were deparaffinized in xylene, rehydrated, 
incubated for 15 min with fresh 0.3% hydrogen peroxide, washed with PBS, and 
heated to 95°C in 10 mM citrate buffer (pH 6.0; 30 min) for Akt1 and Akt2 
antibody staining. Antigen retrieval for slides stained with AMPKα1 and AMPKα2 
antibody was performed in Diva Decloaker, RTU (Biocare Medical; # DV2004G1) 
buffer. Antigen retrieval for sliders stained with Akt1 and Akt2 were performed in 
sodium citrate buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0). 
 
Endogenous peroxidase activity was blocked with Bloxall blocking solution 
(Vector Laboratories; # SP-6000). Next, sections were blocked for 1h with 2.5% 
normal horse serum (Vector Laboratories; #S-2012). AMPKα1, AMPKα2, Akt1, 
and Akt2 antibodies were diluted in Dako background reducing antibody diluent 
(Agilent Dako; #s3022). Primary antibody was incubated with slides for 12 h at 
4°C in a humidifier chamber, washed with TBST (Tris-Buffered Saline and Tween 
20) and incubated with ImmPRESS universal antibody IgG polymer detection kit 
(Vector Laboratories, #MP-7500) for 1h, RT. Antibody reaction was visualized 
with Immpact DAB EqV peroxidase substrate (Vector Laboratories, #SK-4103). 
All sections were counterstained with hematoxylin (VWR; #95057-844) and 
observed by light microscopy. For negative controls, primary antibody was 
omitted from the above protocol.  
 
The number of positive cells was visually evaluated in each core by a 
pathologist, and the staining intensity was classified using a semi-quantitative 
seven-tier system developed by Allred et al. [132, 133]. The system assesses the 
percentage of positive cells (none=0; <10%=1; 10% to 50%, =2; >50%=3) and 
intensity of staining (none=0; weak=1; intermediate=2; and strong=3). 
 
4.3.6 TNBC lung metastasis model 
 
NOD-scid IL2Rgammanull mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). Housing for these animals was maintained in a 
HEPA-filtrated environment within sterilized cages with 12 h light/12 h dark 
cycles. All animal procedures were conducted with approval of and in compliance 
with the University of Kentucky Institutional Animal Care and Use Committee. 
Knockdown of Akt and AMPK isoforms in circulating cancer cells was 
achieved by transient knockdown of protein expression in vitro, as described 
above, and injection of cancer cells intravenously (iv) into mice 48h after 
transfection. Briefly, cells were washed with 1x PBS 48h after transfection, 
trypsinized, counted and resuspended in PBS at a density of 1 x 106 cells per 
100 μL. Cells were kept on ice before intravenous injection. For iv injection of 
MDA-MB-231 GFP cells, NOD-scid IL2Rgammanull mice were anesthetized with 
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isoflurane (induction 4%, maintenance 2%). The viability of cells used for 
inoculation was greater than 95% as determined by Vi-CELL™ XR (Beckman 
Coulter); 1x106 cells were injected per animal. Gentle pressure was applied to 
the inoculation site until there was no visible sign of bleeding. GFP fluorescence 
imaging was performed using an LT-9500 Illumatool/TLS (Lightools Research, 
Encinitas, CA), equipped with an excitation source (470 nm) and filter plate (515 
nm). 
 
4.3.7 MK-2206 in vivo experiment 
 
GFP-expressing MDA-MB-231 cells were treated with MK-2206 (0 or 10 
μM). After 22h, medium was replaced with fresh medium containing MK-2206 (0 
or 10 μM) for an additional 2h. Akt activity is suppressed with MK-2206 treatment 
for 2h, so treatment was renewed for the final 2h to ensure that pAkt inhibition 
was maintained [134, 135]. Cells were then collected and counted before iv 
injection into the tail vein of mice.  
 
4.3.8 Analysis of GFP signal in TNBC lung metastases 
 
ImageJ software was used to evaluate GFP signal in TNBC lung 
metastases. ImageJ is a Java-based image processing program developed at 
the National Institutes of Health and the Laboratory for Optical and 
Computational Instrumentation (LOCI, University of Wisconsin; 
https://imagej.nih.gov/). Photographs of lung metastases were opened in ImageJ 
software and split into channels (Image-Color-Split Channels). Blue and red 
channels were closed, and the green channel was adjusted with threshold 
function (Image-Adjust-Threshold; select B&W in drop-down menu). Next, a 
rectangular selection area was drawn over a lung to perform measurement of 
mean gray values. Analysis properties were set to “area” and “Mean grey value” 
(Analyze-Set Measurement). Mean grey values in the rectangular selection area 
drawn over a lung were analyzed and recorded (Analyze-Measure). To keep the 
area of selection consistent, the rectangular selection area was moved over the 
next lung and the analysis was repeated (Analyze-Measure). 
 
4.3.9 Statistical analysis 
 
Descriptive statistics, including means and standard deviations (SD), are 
presented for each experimental group and displayed in bar graphs while 
frequencies and proportions of IHC score were summarized for Akt and AMPK. 
Comparisons of green fluorescence area were performed using the one-way 
analysis of variance (ANOVA) with Holm’s adjustment for multiple testing 
between groups. The chi-square test for goodness of fit was used to test 
departures from equality of proportions across IHC scores.  p<0.05 was 
considered to indicate a statistically significant difference. Statistical analyses 
were performed using SAS software version 9.4 (SAS Inc., Cary, NC, USA). 
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4.4 Results 
 
4.4.1 Expression of Akt and AMPKα isoforms in TNBC lymph node metastases 
 
Akt and AMPKα promote cellular survival and energy mobilization and 
may facilitate organ colonization during metastatic spread [60, 62, 92, 115, 122, 
123, 136]. We have previously shown that AMPKα1 and AMPKα2 are expressed 
in TNBC patient samples [137]. However, the expression of Akt and AMPKα 
isoforms in TNBC distant metastases is unclear. Therefore, we determined the 
expression and subcellular localization of Akt1, Akt2, AMPKα1, and AMPKα2 in 
45 TNBC lymph node metastases. Figure 4.1A-D indicates the cytoplasmic 
scoring distribution and representative staining for each isoform in the TNBC 
patient samples. Akt1, Akt2, and AMPKα1 received scores of 5 or 6 in over 70% 
of cases, indicating intense and widespread cytoplasmic expression among the 
lymph node metastases (Figure 4.1A-C). Chi-square tests indicated statistically 
significant higher IHC scores for Akt1, Akt2, and AMPKα1. Figures 4.2, 4.3, and 
4.4 contain all IHC staining images for Akt1, Akt2, and AMPKα1. AMPKα2 had 
slightly lower scores than the other proteins, with over 80% of samples being 
scored as a 4 or 5 (Figure 4.1D). Moreover, AMPKα2 was not expressed in the 
cytoplasm in 11% of cases. These findings suggest that cytoplasmic expression 
of AMPKα2 is moderately strong and widespread among the patient samples. 
Chi-square tests also indicated statistically significant higher IHC scores for 
AMPKα2. Figure 4.5 contains all IHC staining images for AMPKα2. Taken 
together, these results suggest that Akt1, Akt2, AMPKα1, and AMPKα2 may play 
important roles in facilitating TNBC metastasis to distant sites. 
 
Figure 4.1E compares the subcellular localization of Akt1, Akt2, AMPKα1, 
and AMPKα2 within the TNBC lymph node metastases. In most samples, Akt1, 
Akt2, and AMPKα1 were expressed in only the cytoplasm. Akt1, Akt2, and 
AMPKα1 were found in both the nucleus and cytoplasm in a minority of cases, 
but no samples contained only nuclear expression. AMPKα2 had a substantially 
different subcellular localization pattern than Akt1, Akt2, or AMPKα1. AMPKα2 
was expressed in both the nucleus and the cytoplasm in a majority of samples. In 
addition, AMPKα2 was expressed in only the cytoplasm in 4 samples. This 
analysis suggests that AMPKα2 is preferentially localized in the nucleus 
compared to AMPKα1 or Akt isoforms. Taken together, these findings indicate 
that Akt1, Akt2, and AMPKα1 are predominantly expressed in the cytoplasm of 
TNBC lymph node metastases while AMPKα2 is found in both the nucleus and 
cytoplasm. 
 
4.4.2 Role of Akt and AMPKα isoform expression on proteins that regulate 
apoptosis induction and invasion in TNBC cells 
 
Survival during transport and extravasation through the vessel wall are 
essential steps for cells to establish distant metastases [127, 128]. Therefore, 
proteins that prevent apoptosis induction or facilitate invasion may play a major 
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role in promoting TNBC lung colonization. Akt1 regulates apoptosis induction in 
MDA-MB-231 cells, but the ability of Akt2 and AMPKα isoforms to control 
apoptosis in TNBC cells is unclear [136]. Moreover, the effect of Akt or AMPKα 
isoforms on many invasion-promoting proteins in TNBC cells is unknown. 
 
We next determined the differential expression of invasive proteins in 
TNBC cells after knockdown of Akt and AMPKα isoforms. Using siRNA 
transfection, levels of Akt1, Akt2, AMPKα1, or AMPKα2 were depleted in MDA-
MB-231 and MDA-MB-468 cells (Figure 4.6). As shown in Figure 4.6A, 
knockdown of Akt2 decreased expression of Snail and Claudin-1 in MDA-MB-231 
and MDA-MB-468 cells. Silencing Akt1 did not consistently affect expression 
levels of various invasive proteins in MDA-MB-231 and MDA-MB-468 cells 
(Figure 4.6A). Similarly, knockdown of AMPKα1 or AMPKα2 did not consistently 
impact expression of invasive proteins in our panel of TNBC cells (Figure 4.6B). 
Taken together, these findings indicate that Akt2 regulates expression of proteins 
that may promote extravasation in circulating TNBC cells. 
 
Next we determined whether Akt and AMPKα isoforms control apoptosis 
induction in TNBC cells. siRNA transfection was used to diminish expression of 
Akt1, Akt2, AMPKα1, or AMPKα2 in MDA-MB-231 and MDA-MB-468 cells 
(Figure 4.7). As shown in Figure 4.7A, Akt1 knockdown induced PARP cleavage 
in both MDA-MB-231 and MDA-MB-468 cells. Silencing Akt2 also led to robust 
PARP cleavage in MDA-MB-468 cells. Neither AMPKα1 nor AMPKα2 knockdown 
induced PARP cleavage in MDA-MB-231 cells (Figure 4.7B). These findings 
suggest that either Akt1 or Akt2 knockdown promotes apoptosis induction in 
TNBC cells. We then determined how silencing Akt1 or Akt2 impacted 
expression of Bcl2 family proteins, which regulate apoptosis induction. Akt1 
knockdown increased the expression of Bim, a promoter of apoptosis, in MDA-
MB-231 and MDA-MB-468 cells (Figure 4.7C). Silencing Akt2 reduced levels of 
Mcl-1, an anti-apoptotic protein, in both MDA-MB-231 and MDA-MB-468 cells 
(Figure 4.7C). Taken together, these findings indicate that Akt1 and Akt2 prevent 
apoptosis in TNBC cells by reducing Bim expression or upregulating Mcl-1 levels, 
respectively. 
 
4.4.3 Akt1 and Akt2 promote lung colonization of circulating MDA-MB-231 cells 
 
The ability of individual Akt and AMPKα isoforms to regulate TNBC lung 
colonization is unknown. Moreover, the effect of combined inhibition of Akt and 
AMPKα isoforms on lung colonization of circulating TNBC cells is unclear. 
Therefore, we determined how silencing Akt1, Akt2, AMPKα1, AMPKα2, or 
AMPKα1/2—alone or in combination—affects lung colonization of MDA-MB-231 
cells. We selected a transient transfection model to examine lung colonization of 
TNBC cells. Transfection with siRNA leads to cleavage and subsequent 
degradation of the targeted mRNA sequence [138, 139]. As a result, the mRNA 
cannot be translated into the amino acid residues that comprise the protein of 
interest. Once the existing cellular proteins are degraded, the siRNA-induced 
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decreases are apparent. Robust decreases in target protein levels in Figs 2 and 
3 were observed at 72h after transfection. Therefore, transfected cells were 
prepared for injection into mice to ensure that maximum knockdown in protein 
expression was present while the cells were in circulation. As a result, 
knockdown would impact survival during transport or extravasation into lung 
parenchyma, but it would not affect steps after invasion—such as colony 
formation and proliferation. Thus, this model allows us to establish whether Akt 
and AMPKα isoforms affect the ability of circulating TNBC cells to colonize lungs. 
 
First, siRNA transfection was used to generate transient knockdown of 
Akt1 or Akt2 in GFP-expressing MDA-MB-231 cells, which were injected into the 
tail vein of mice after 48h. Figure 4.8A indicates that knockdown of either Akt1 or 
Akt2 dramatically decreased MDA-MB-231 invasion into lung parenchyma. 
Silencing Akt1 or Akt2 blocked metastasis to a similar degree. Quantification of 
green fluorescence intensity with ImageJ indicated that both reductions were 
statistically significant (Figure 4.8B). Taken together, these results suggest that 
Akt1 and Akt2 promote lung colonization of circulating TNBC cells. 
 
Next, we determined how combined inhibition of AMPKα1 and Akt1 
affected apoptosis induction and lung colonization in MDA-MB-231 cells. 
Depleting Akt1 levels induced PARP cleavage and increased Bim expression, 
but combined knockdown with AMPKα1 did not enhance either effect (Figure 
4.9A). We then reduced expression of AMPKα1 and Akt1 alone or in combination 
in GFP-expressing MDA-MB-231 cells before injecting into mice. As shown in 
Figure 4.9B, silencing AMPKα1 did not affect the ability of cells to invade into 
murine lungs. Suppressing Akt1 expression prevented MDA-MB-231 lung 
metastasis, which is consistent with the finding from Figure 4.8. However, 
combined knockdown of AMPKα1 and Akt1 did not inhibit metastasis more than 
silencing Akt1 alone. We next depleted levels of AMPKα2 in GFP-expressing 
MDA-MB-231 cells and injected into mice. As noted in Figure 4.9C, AMPKα2 
knockdown did not affect metastatic spread of MDA-MB-231 cells to the lungs. 
Since neither AMPKα1 nor AMPKα2 alone impacted lung colonization of MDA-
MB-231 cells, we then examined how AMPKα1/2 affects lung metastasis. We 
suppressed expression of AMPKα1/2 in GFP-expressing MDA-MB-231 cells 
before injecting into mice. As shown in Figure 4.9D, silencing AMPKα1/2 did not 
impact the ability of MDA-MB-231 cells to invade into lung parenchyma. Taken 
together, these findings indicate that Akt1 and Akt2 facilitate lung colonization of 
circulating TNBC cells while AMPKα does not impact TNBC lung colonization. 
 
4.4.4 Akt1 and Akt2 promote TNBC lung colonization independent of Akt activity 
 
We showed that silencing Akt1 or Akt2 dramatically decreased lung 
colonization of circulating MDA-MB-231 cells. However, our prior experiments did 
not establish whether this effect was due to (1) reduced Akt activity secondary to 
knockdown, or (2) decreased expression of Akt1 and Akt2. To address this 
question, we suppressed Akt activity in MDA-MB-231 cells with MK-2206, an 
 
 
61 
allosteric Akt inhibitor, prior to iv cell injection. As shown in Figure 4.10A, we 
confirmed that MK-2206 treatment reduced Akt activity in MDA-MB-231 cells. 
Figures 4.10B and 4.10C indicate that inhibiting Akt activity did not affect MDA-
MB-231 lung colonization. Taken together, these findings suggest that the ability 
of Akt1 and Akt2 to promote lung colonization of circulating TNBC cells is 
independent of Akt activity. Reducing metastatic potential of TNBC by 
suppressing Akt1 and/or Akt2 expression is a potentially promising therapeutic 
strategy that may directly improve patient survival. 
 
4.5 Discussion 
 
Preventing metastatic spread of TNBC is crucial to improving patient 
survival. Akt and AMPK are two key proteins that serve vital functions for cancer 
cells during stress. The Akt signaling cascade promotes cellular survival by 
inhibiting apoptosis and facilitates cellular growth by stimulating cell cycle 
progression. AMPK is an important regulator of metabolism and helps cells 
maintain energy homeostasis in times of stress. Moreover, Akt and AMPK 
reciprocally regulate each other during matrix attachment and detachment in 
breast cancer [115]. The existence of this reciprocal regulatory loop prompted 
our interest in targeting both pathways together to block metastasis. We 
hypothesized that combined inhibition of Akt and AMPK would prevent TNBC 
lung colonization more than targeting either pathway alone, thereby improving 
patient survival. 
 
Mutations that activate the PI3K/Akt/mTOR pathway are frequently found 
in breast cancer [140]. However, the ability of individual Akt isoforms to mediate 
metastasis of TNBC cells is not well understood. We found that silencing Akt1 
dramatically decreased lung colonization of circulating TNBC cells and induced 
PARP cleavage and Bim expression.  Prior work has found that Akt1 maintains 
the viability of tumor-initiating cells by reducing Bim expression [136]. Therefore, 
our results indicate that Akt1 may support lung metastasis of circulating TNBC 
cells by preventing apoptosis induction. To our knowledge, this is the first study 
to establish that Akt1 expression promotes the in vivo metastatic potential of 
TNBC cells. Previous work has found that Akt1 blocks metastasis of other breast 
cancer subtypes [104-106]. Akt1 inhibits invasion of ER+ breast cancer cells, and 
Akt1 overexpression attenuates HER2-mediated metastasis of murine mammary 
tumors [104-106]. TNBC is a very aggressive disease that is 4x more likely to 
metastasize to viscera than non-TNBCs within the first 5 years [141]. Therefore, 
TNBC metastasis may be promoted by proteins that do not facilitate spread of 
other cancers. Our findings suggest that Akt1 is a key regulator of lung 
colonization in TNBC cells. 
 
Akt2 is more frequently amplified in cancer cells than Akt1, but its ability to 
regulate TNBC lung colonization is also unknown [92]. We found that silencing 
Akt2 significantly reduced TNBC lung colonization and suppressed expression of 
Snail, Claudin-1, and the anti-apoptotic protein Mcl-1. Claudin-1 promotes the 
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invasive potential of nasopharyngeal carcinoma cells, and Snail is required for 
TNBC cells to invade into lymph nodes [142, 143]. Therefore, our findings 
suggest that Akt2 may promote lung metastasis of circulating TNBC cells two 
ways: (1) facilitating extravasation through the vessel wall and into lung 
parenchyma and (2) preventing apoptosis induction. To our knowledge, this is 
the first study to identify Akt2 as a key mediator of lung colonization in circulating 
TNBC cells. Prior work has indicated that Akt2 facilitates metastasis of other 
breast cancer subtypes [105, 106]. Akt2 promotes the migration and invasion of 
ER+ breast cancer cells, and Akt2 overexpression increases HER2-mediated 
metastasis of murine mammary tumors [105, 106]. Our findings suggest that Akt2 
is also an important regulator of metastasis in TNBC cells. 
 
Akt1 and Akt2 facilitate TNBC lung colonization independent of Akt 
activity. We showed that silencing Akt1 or Akt2 does not correlate with a 
substantial reduction in pAkt expression. This is most likely due to compensatory 
phosphorylation of the isoform that is still present within the cells. Despite a 
corresponding reduction in pAkt levels, knockdown of Akt1 or Akt2 significantly 
suppressed TNBC metastasis. Other studies have also found a non-kinase 
function for Akt [144, 145]. Akt1 has been shown to reduce toll-like receptor 
signaling in a kinase-independent fashion [144]. Moreover, Akt promotes cell 
survival in a kinase-independent manner and instead relies on its pleckstrin 
homology domain [145]. Akt1 and Akt2 may facilitate survival of circulating TNBC 
cells in a similar manner, but further work is needed to establish the underlying 
mechanisms. A prior study has found that overexpression of pAkt is correlated 
with an increased rate of brain metastasis in lung cancer patients [146]. Our 
findings suggest that the role of pAkt may vary between cancer types or that pAkt 
mainly stimulates growth of cells that have already colonized distant organs. 
 
Suppressing Akt1 and/or Akt2 expression is a novel therapeutic strategy 
that could be implemented for TNBC patients who are resistant to current 
therapeutic regimens. Our findings indicate that pharmacological reduction of 
Akt1 and/or Akt2 expression in TNBC patients with refractory tumors may 
prevent metastatic spread, thereby directly improving survival. Current clinical 
trials are focused on developing Akt inhibitors as therapeutic agents for breast 
cancer patients. However, we suggest that future studies should identify agents 
that can decrease Akt1 and/or Akt2 expression and evaluate their ability to limit 
metastasis of non-responsive TNBC.  
 
In addition to Akt1 and Akt2, we also studied how AMPKα isoforms impact 
lung colonization. AMPKα is a major metabolic regulator that may balance 
energy demand during different stages of metastasis. When cells detach from a 
matrix, they are unable to import glucose and instead must increase ATP 
synthesis through other pathways [88]. AMPKα’s ability to mobilize energy via 
different metabolic pathways suggests that it may have an important role in 
restoring energy homeostasis for circulating cells. Moreover, fatty acid synthesis 
and oxidation—both of which are regulated by AMPKα—have been reported to 
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promote metastasis [89]. Prior studies have found that AMPKα affects TNBC 
metastasis in an isoform-dependent fashion. AMPKα1 prevents metastatic 
spread of TNBC cells, while AMPKα2 promotes metastasis of TNBC cells [90, 
91]. However, the specific stages of metastasis that are controlled by AMPKα1 
and AMPKα2 in TNBC cells is unclear. In addition, combined inhibition of Akt and 
AMPKα isoforms has not been studied. We found that transiently silencing 
AMPKα1, AMPKα2, or AMPKα1/2 alone did not affect lung colonization of 
circulating MDA-MB-231 cells. Moreover, AMPKα knockdown did not 
synergistically block TNBC lung metastasis when combined with Akt isoform 
knockdown. These findings suggest that AMPKα1, AMPKα2, and AMPKα1/2 do 
not impact lung colonization of circulating MDA-MB-231 cells.  
 
Our findings expand on these prior studies, which used stable knockdown 
or overexpression cells instead of transiently transfected cells [90, 91]. Unlike our 
experimental design, stable cell lines will not lose knockdown or overexpression 
after extravasation into tissue. As a result, previous work has not delineated 
whether AMPKα isoforms regulate metastasis of circulating TNBC cells or 
regulate proliferation of established microcolonies. Our study is able to 
differentiate metastatic stages that precede lung colonization from those that 
follow lung colonization. Our findings indicate that neither AMPKα1 nor AMPKα2 
impact survival or extravasation of circulating TNBC cells. However, AMPKα has 
been shown to affect TNBC cell growth [60, 62, 137]. We have previously 
reported that AMPKα1 and AMPKα2 promote cell cycle progression and 
proliferation in TNBC cells [137]. Moreover, pharmacological activators of 
AMPKα have also reduced growth and cell cycle progression of TNBC cells [67, 
73, 147]. Therefore, the major effect of AMPKα isoforms on TNBC metastasis 
may involve growth regulation of cells that have already survived during transport 
and extravasated into tissue. 
 
In summary (Figure 4.10D), we have shown that reducing Akt1 or Akt2 
expression prevents lung colonization of TNBC cells. Akt1 facilitates lung 
metastasis by inhibiting apoptosis induction, while Akt2 promotes lung metastasis 
by enabling extravasation through the vessel wall and into surrounding tissue. 
These reductions in metastasis are independent of Akt activity. Silencing 
AMPKα1, AMPKα2, or AMPKα1/2 does not reduce lung colonization or 
synergistically block lung metastasis when combined with Akt isoform 
knockdown. Importantly, suppressing Akt1 and/or Akt2 expression is a potentially 
promising therapeutic strategy that could reduce lung colonization and thus 
decrease mortality among TNBC patients. 
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Figure 4.1 Akt1, Akt2, AMPKα1, and AMPKα2 expression in TNBC lymph 
node metastases. 
Analysis of (A) Akt1, (B) Akt2, (C) AMPKα1, and (D) AMPKα2 expression in the 
cytoplasm of TNBC lymph node metastases. Samples were scored on scales of 
0-3 for both intensity and distribution percentage, and the values were added 
together (n = 45). Representative IHC staining for each protein is demonstrated 
below each pie chart. (E) Distribution of Akt1, Akt2, AMPKα1, and AMPKα2 
cytonuclear localization in TNBC lymph node metastases (n = 45; * indicates 
p<0.0001). 
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Figure 4.2 Akt1 is expressed in TNBC lymph node metastases. 
IHC staining of Akt1 in TNBC lymph node metastases. Samples were scored on 
scales of 0-3 for both intensity and distribution percentage and then added 
together (n = 45). 
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Figure 4.3 Akt2 is expressed in TNBC lymph node metastases. 
IHC staining of Akt2 in TNBC lymph node metastases. Samples were scored on 
scales of 0-3 for both intensity and distribution percentage and then added 
together (n = 45). 
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Figure 4.4 AMPKα1 is expressed in TNBC lymph node metastases. 
IHC staining of AMPKα1 in TNBC lymph node metastases. Samples were scored 
on scales of 0-3 for both intensity and distribution percentage and then added 
together (n = 45). 
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Figure 4.5 AMPKα2 is expressed in TNBC lymph node metastases. 
IHC staining of AMPKα2 in TNBC lymph node metastases. Samples were scored 
on scales of 0-3 for both intensity and distribution percentage and then added 
together (n = 45). 
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Figure 4.6 Akt2 promotes migratory and invasive phenotypes of TNBC 
cells. 
(A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM of siRNA 
targeting Akt1 or Akt2. Expression of Akt1, Akt2, ZO-1, Claudin-1, E-cadherin, 
Vimentin, β-catenin, and Snail was analyzed by western blot 72h after 
transfection. (B) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 
nM of siRNA targeting AMPKα1 or AMPKα2. Expression of AMPKα1, AMPKα2, 
β-catenin, Snail, ZO-1, E-cadherin, and Zeb1 was analyzed by western blot 72h 
after transfection. NTC, Non-targeting control was used as a negative control. 
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Figure 4.7 Akt1 and Akt2 suppress apoptosis induction in TNBC cells. 
(A) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 nM siRNA 
targeting Akt1 or Akt2. Expression of Akt1, Akt2, and cleaved PARP was 
detected with western blot 72h after transfection. (B) MDA-MB-231 cells were 
transfected with 50 nM siRNA targeting AMPKα1 or AMPKα2. Expression of 
AMPKα1, AMPKα2, and cleaved PARP was detected with western blot 72h after 
transfection. (C) MDA-MB-231 and MDA-MB-468 cells were transfected with 50 
nM siRNA targeting Akt1 or Akt2. Expression of pAkt, Akt1, Akt2, Bcl-xL, Bcl-2, 
Mcl-1, Bim, Bad, and BID was detected with western blot 72h after transfection. 
Non-targeting control (NTC) was used as a negative control. 
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Figure 4.8 Akt1 and Akt2 promote lung colonization of TNBC cells. 
(A) MDA-MB-231-GFP cells were transfected with 50 nM of siRNA targeting Akt1 
or Akt2. Cells were collected 48h after transfection and injected intravenously 
into NSG mice. MDA-MB-231 lung metastasis was visualized with fluorescence 
imaging 28d later. (B) ImageJ was used to quantify overall metastatic burden in 
mice lungs. * indicates p<0.05. 
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Figure 4.9 AMPKα isoforms do not facilitate lung colonization of TNBC 
cells. 
(A) MDA-MB-231 cells were transfected with siRNA targeting Akt1, AMPKα1, or 
Akt1/AMPKα1. Transfection concentrations were: (1) individual siRNA: 50 nM, (2) 
combination siRNA: 50 nM each (100 nM total), and (3) NTC: 100 nM. 
Expression of Akt1, AMPKα1, cleaved PARP, and Bim was detected with 
western blot 72h after transfection. (B) MDA-MB-231-GFP cells were transfected 
with siRNA targeting Akt1, AMPKα1, or Akt1/AMPKα1. Transfection 
concentrations were: (1) individual siRNA: 50 nM, (2) combination siRNA: 50 nM 
each (100 nM total), and (3) NTC: 100 nM. Cells were collected 48h after 
transfection and injected intravenously into NSG mice. MDA-MB-231 lung 
metastasis was visualized with fluorescence imaging 40d later. (C) MDA-MB-
231-GFP cells were transfected with siRNA targeting AMPKα2. Transfection 
concentrations were 50 nM for NTC and 50 nM for AMPKα2. Cells were collected 
48h after transfection and injected intravenously into NSG mice. MDA-MB-231 
lung metastasis was visualized with fluorescence imaging 36d later. Lungs were 
subsequently removed and photographed. (D) MDA-MB-231-GFP cells were 
transfected with siRNA targeting AMPKα1/2. Transfection concentrations were 
100 nM for NTC and 50 nM for AMPKα1/2. Cells were collected 48h after 
transfection and injected intravenously into NSG mice. MDA-MB-231 lung 
metastasis was visualized with fluorescence imaging 36d later. 
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Figure 4.10 Akt1 and Akt2 promote lung colonization of TNBC cells 
independent of Akt activity. 
(A) MDA-MB-231 cells were treated with 10 μM MK-2206 for 22h. Fresh medium 
containing 10 μM MK-2206 was then added for 2h more. Expression of pAkt was 
subsequently analyzed with western blot with Akt (pan) and β-actin as loading 
controls. (B) MDA-MB-231-GFP cells were treated with 10 μM MK-2206 for 22h. 
Fresh medium containing 10 μM MK-2206 was then added for 2h more. Cells 
were subsequently collected and injected intravenously into NSG mice. MDA-
MB-231 lung metastasis was visualized with fluorescence imaging 46d later.    
(C) Quantification of green fluorescence intensity from lungs in (B) using ImageJ. 
(D) Summary diagram showing that silencing Akt1 or Akt2 prevents TNBC lung 
colonization by inducing apoptosis or inhibiting invasion, respectively, while 
knockdown of AMPKα1 or AMPKα2 does not impact TNBC lung colonization. 
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CHAPTER 5. CONCLUSIONS 
 
TNBC makes up 15-20% of all breast cancers and is classified by the 
absence of the estrogen receptor, the progesterone receptor, and the HER2 
protein [3-5]. TNBC is a very aggressive disease that affects a younger patient 
population and has a higher metastatic rate than other breast cancers [3-5, 8, 9]. 
Furthermore, TNBC comprises a diverse group of tumors that includes BL1, BL2, 
M, and LAR [11, 17]. For the most part, these tumors have proven refractory to 
targeted therapy. Instead, patients generally receive NAC in addition to surgery 
and radiotherapy. The NAC standard of care includes an anthracycline, a taxane, 
and potentially a DNA alkylating agent, but platinum agents are currently under 
investigation and also appear to provide benefit [3, 4, 9, 17, 24]. This regimen is 
successful for certain patients, but a subset of TNBC patients have tumors that 
are resistant to both NAC and localized therapies [32]. Patients with RD after 
receiving NAC are more likely to experience recurrent disease and have lower 
survival than those who achieve pCR [8, 13, 39-41, 43]. As a result, there is an 
urgent need to develop strategies that can improve treatment in patients who 
have RD after receiving NAC. In particular, those with stage II or III TNBC that is 
refractory to NAC may benefit from novel therapeutics. 
 
AMPK and Akt are important metabolic regulators that have been 
implicated in cancer progression. The purpose of this project was to determine 
whether AMPK and Akt can be targeted to enhance TNBC therapy or reduce 
TNBC metastasis. 
 
5.1 Role of AMPKα in TNBC – An Apparent Dichotomy  
 
Both AMPKα1 and AMPKα2 were expressed in TNBC patient samples, 
PDXs, and cell lines. Moreover, both isoforms promoted G1 cell cycle 
progression and cell proliferation potentially through p53 downregulation. 
AMPKα1 also facilitated basal and compensatory glycolysis. These findings 
indicate that AMPKα1 and AMPKα2 have a tumor promoter role in TNBC. 
However, treatment with the AMPKα activator FND-4b induced cell cycle arrest, 
suppressed mTOR signaling, and reduced TNBC proliferation. The results from 
this study suggest that AMPKα has a tumor suppressor role. Reconciling this 
apparent dichotomy is of utmost importance before therapeutics targeting 
AMPKα are used in the clinic for treating TNBC. An attempted rationalization is 
below. 
 
Under physiological conditions, AMPKα maintains energy homeostasis by 
increasing ATP production through glycolysis and fatty acid oxidation [47, 48, 60, 
62]. In addition, AMPKα can promote survival in stressful conditions through the 
autophagy pathway [45]. These functions ensure that cells remain healthy and 
able to proceed through the cell cycle and undergo mitosis. However, 
administration of a small molecule activates AMPKα to a supraphysiological level 
[54]. When this occurs, AMPKα may sense that the cell desperately needs ATP 
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and therefore alter signaling through a wide variety of metabolic pathways. 
AMPKα can reduce the rates of fatty acid synthesis and protein synthesis by 
inhibiting acetyl CoA carboxylase and mTOR, respectively [47, 48]. However, 
anabolic pathways can also control cell cycle progression [54, 111]. For instance, 
mTOR controls cyclin D1 levels through eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1) [148]. Reduced mTOR signaling could therefore result 
in lower levels of cyclin D1 and lead to a G1 cell cycle arrest. Moreover, fatty acid 
synthesis is required for cells to progress from the G2 phase into mitosis, and 
decreased lipid synthesis could induce arrest at the G2-M checkpoint [54]. 
Suppressed signaling through anabolic pathways due to supraphysiological 
AMPKα activation may overcome AMPKα’s ability to promote cell cycle 
progression and instead induce cell cycle arrest. 
 
Another reason why AMPKα activators reduce cellular proliferation may lie 
in their respective mechanisms of action. Many such compounds do not activate 
AMPKα directly; instead, they induce cellular metabolic damage, which leads to 
lower ATP levels and higher AMP levels. These changes in turn induce AMPKα 
activation. For instance, 2-deoxyglucose blocks glycolysis while metformin 
inhibits the mitochondrial respiratory chain [76]. These metabolic deficiencies will 
likely activate other cellular pathways in addition to AMPKα. A recent study has 
shown that many common AMPKα activators suppress proliferation in AMPKα 
knockdown cells [76]. These findings suggest that other signaling pathways have 
a critical role in modulating cellular proliferation in response to metabolic insults. 
Moreover, these results call into question the ability of AMPKα activation to 
decrease cellular growth. Activation of AMPKα may be better understood as an 
indicator of metabolic damage instead of as a primary regulator of cellular 
proliferation. 
 
5.2 AMPKα Isoforms Have Different Subcellular Localizations 
 
AMPKα1 was localized in the cytoplasm of TNBC patient samples and 
was predominantly found in the cytoplasm of TNBC lymph node metastases. 
AMPKα2, however, was mostly found in both the cytoplasm and nucleus in both 
the TNBC patient samples and the TNBC lymph node metastases. These 
findings indicate that AMPKα2 is preferentially expressed in the nucleus 
compared to AMPKα1. Nuclear expression of AMPKα2 has previously been 
observed, and AMPKα2 has a nuclear localization sequence [120, 149, 150]. 
AMPKα1 does not have the same sequence [150]. While further work is needed, 
it is possible that AMPKα2 regulates nuclear signaling—potentially controlling 
gene expression through the phosphorylation of transcription factors. In TNBC 
cells, silencing AMPKα2 led to a less robust reduction in cyclin D1 expression 
than AMPKα1 knockdown. However, TNBC cells with AMPKα2 knockdown 
proliferated slower than those with AMPKα1 knockdown. This suggests that 
AMPKα2 may affect cellular proliferation via other mechanisms that have not 
been determined yet. Future studies will need to delineate signaling pathways 
that are uniquely controlled by AMPKα2. 
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5.3 Targeted AMPKα Therapies Should be Developed 
 
Regardless of mechanism, compounds that activate AMPKα can suppress 
cancer cell proliferation and may have a role in future chemotherapeutic 
regimens. AMPKα has wide-ranging effects in the body, so it is necessary to 
consider the side effects and potential toxicities that accompany prolonged 
AMPKα activation. First, AMPKα promotes fatty acid oxidation and prevents 
triglyceride synthesis in the liver and adipose tissue [151]. This will mobilize 
energy that may be necessary to maintain important bodily functions during 
chemotherapy. Next, AMPKα inhibits DNA replication [151]. Supraphysiological 
activation of AMPKα could prevent normal cells from successfully undergoing 
mitosis. Rapidly proliferating cells, such as hair follicles, may be most susceptible 
to this blockade, so a potential side effect is hair loss. Third, activation of AMPKα 
has been shown to stimulate food consumption and increase body weight in mice 
[151]. Replicating such an effect in TNBC patients may reduce cancer cachexia 
and improve treatment outcome. In addition, AMPKα positively regulates 
endothelial nitric oxide synthase (eNOS) to ensure that blood flow is maintained 
to important organs [151]. Finally, AMPKα can phosphorylate serine residues on 
the cystic fibrosis transmembranal conductance regulator (CFTR), a membrane 
protein in lung secretory cells that channels chloride ions into and out of a cell 
[151]. AMPKα phosphorylates residues that normally keep the chloride channel 
closed, and AMPKα activation should prevent a buildup of chloride ions and 
mucus within lung cells [151]. Thus, AMPKα activation may provide therapeutic 
benefit for patients suffering from cystic fibrosis [151]. 
 
Developing therapeutics that selectively target AMPKα in TNBC cells 
needs further exploration. Current AMPKα activators have opposite effects in 
different parts of the body [151]. For instance, leptin and metformin block AMPKα 
activity in the hypothalamus but induce its activation in peripheral tissues [151]. 
Therefore, administering either agent to a TNBC patient may reduce appetite and 
prevent weight gain—potentially worsening the effects of cachexia. Oncologists 
should consider how administering metformin will impact a TNBC patient’s ability 
to maintain weight throughout therapy. Moreover, ghrelin and cannabinoids 
inhibit AMPKα in adipose tissue and the liver but increase its activation in the 
hypothalamus [151]. Treatment with a cannabinoid may stimulate appetite and 
prevent cachexia in TNBC patients, but this could also interfere with the body’s 
ability to generate energy from triglycerides. Decreased energy production may 
increase fatigue and drowsiness among TNBC patients. These two examples 
indicate why it is imperative to identify novel AMPKα activators that have tissue-
specific effects before they are widely used in the clinic for TNBC treatment. 
 
5.4 Reducing Akt1 Expression Sensitizes TNBC to Radiation 
 
Reducing Akt1 expression for stage II and III TNBC patients undergoing 
radiotherapy is a novel therapeutic strategy that could enhance the efficacy of 
radiation. Improving the effectiveness of radiation therapy in TNBC patients with 
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radioresistant tumors should directly reduce recurrence and improve survival. 
Moreover, pharmacological suppression of Akt1 expression at the onset of 
radiation-induced apoptosis with MK-2206 synergistically promoted apoptosis. 
This finding is particularly important because it suggests that radiation therapy 
can be potentiated in TNBC patients with administration of a radiosensitizer for 
only a short time period. By limiting exposure to pharmacological agents that may 
also affect nonmalignant cells, TNBC patients will experience fewer side effects 
and find treatment more tolerable. In addition, patients may be able to receive 
lower radiation doses, which would likely widen the therapeutic index. Apoptosis 
induction occurred between 48h and 72h after radiotherapy in TNBC cells, and 
Akt1 suppression 48h after radiation therapy was sufficient to potentiate 
radiation-induced apoptosis in vitro. These timepoints will most likely be different 
in TNBC patients, so further studies need to be conducted in vivo. In addition, 
current radiotherapy regimens utilize a fractionated approach in which radiation is 
usually delivered 5 consecutive days for 5 weeks. This protocol differs from the 
single-dose approach that was used to examine radiosensitivity. However, a 
fractionated approach was able to induce apoptosis 96h after the initial treatment 
in TNBC cells. It is likely that reducing Akt1 expression will also induce apoptosis 
with the fractionated protocol. Future work will need to determine the optimal 
timing to potentiate radiation-induced apoptosis with this strategy. 
 
Enhancing radiotherapy in patients with stage II or III TNBC by reducing 
Akt1 expression will also reduce the amount of ionizing radiation (IR) that must 
be delivered. Side effects from IR include fatigue, skin irritation, and lymphedema 
[152]. For the most part, these side effects should be well tolerated by patients. 
However, IR can also contribute to the development of a secondary cancer [153]. 
The chance of this happening is low, but it is imperative to minimize the risk of an 
additional cancer in patients who already have refractory TNBC. Decreasing the 
amount of IR that must be administered will directly reduce toxicity and the 
probability of a patient getting a second cancer.  
 
Future work should focus on identifying novel agents that can reduce Akt1 
expression. This will most likely involve a rational drug design approach that will 
include collaborations between cancer biologists, organic chemists, and 
computational chemists. Although administration of MK-2206 suppressed Akt1 
and enhanced radiation-induced apoptosis, the effects were somewhat mild. 
Efforts should now be focused on developing a compound that can reduce Akt1 
expression to a similar degree as siRNA knockdown. If that is possible, then it is 
likely that such an agent would be able to potentiate radiation-induced apoptosis 
to a greater degree than MK-2206. Further in vitro and in vivo studies should be 
conducted to analyze the ability of the drug to act as a radiosensitizer in TNBC. 
Once a more potent agent has been identified and successfully evaluated, a 
clinical trial could also be initiated to establish its safety and efficacy in a target 
patient population—such as those with NAC-resistant stage II or III TNBC. 
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5.5 Suppressing Akt1 or Akt2 Expression Reduces TNBC Lung Metastasis 
 
 Reducing expression of Akt1 and/or Akt2 to suppress metastasis should 
be considered as a novel therapeutic strategy for patients with stage II or III 
TNBC that is refractory to NAC. Silencing Akt1 or Akt2 reduced lung colonization 
by inducing apoptosis or decreasing invasion, respectively. These results 
suggest that both Akt1 and Akt2 are key mediators of TNBC metastasis. 
However, knockdown of AMPKα1, AMPKα2, or AMPKα1/2 did not impact lung 
colonization of TNBC cells. In addition, combined targeting of AMPKα1 and Akt1 
did not reduce metastasis more than targeting Akt1 alone. These results suggest 
that AMPKα isoforms do not affect TNBC survival during transport or 
extravasation through a vessel. Instead, the primary role of AMPKα isoforms on 
TNBC metastasis seems to involve growth regulation of cells that have already 
colonized distant organs. Administering an Akt suppressor during adjuvant 
chemotherapy could prevent distant metastases in patients with non-responsive 
TNBC. 
 
Future efforts should focus on identifying and synthesizing 
pharmacological agents that can selectively reduce Akt1 or Akt2 expression to a 
degree that is similar to genetic knockdown. MK-2206 reduced Akt1 levels and 
induced radiosensitivity in TNBC cells, but treatment with this compound was 
unable to prevent lung colonization. This may be because a stronger reduction in 
Akt1 expression is needed to limit metastatic spread. However, MK-2206’s 
inability to reduce TNBC metastasis clearly indicates that the effect is 
independent of Akt activity. Developing a more potent suppressor of Akt isoform 
expression should follow a similar protocol as that discussed in section 5.4. After 
that, it will be vital to test the ability of the compound to reduce distant metastasis 
in TNBC patients with stage II or III disease who are refractory to NAC.  
 
5.6 Akt1 and Akt2 Promote TNBC Metastasis Independent of Akt Activity 
 
Silencing either Akt1 or Akt2 reduced TNBC metastatic burden in lung 
tissue in a manner that was independent of their kinase activity. As shown in 
Figure 4.8C, suppression of Akt1 or Akt2 expression in MDA-MB-231 cells did 
not induce a concomitant decrease in pAkt expression. Akt2 knockdown was 
associated with an increase in Akt activity. The maintenance of pAkt expression 
after Akt isoform knockdown is most likely due to compensatory phosphorylation 
of the isoform that is still present at basal levels. Other studies have also found 
that Akt has a non-kinase role [144, 145]. Akt1 decreases toll-like receptor 
signaling in an Akt-independent manner [144]. In addition, Akt promotes survival 
of cancer cells in a fashion that is independent of its kinase function and instead 
depends on its pleckstrin homology (PH) domain [145]. Akt1 and Akt2 may also 
rely on the PH domain to facilitate survival of TNBC cells, but further work will be 
needed to establish the underlying mechanisms. 
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5.7 Potential Drug Delivery Method for TNBC 
 
 Pharmacological agents that selectively activate AMPKα or reduce 
expression of Akt1 or Akt2 should be developed and tested in TNBC patients. 
However, identifying targeted therapies has been difficult because TNBC lacks 
hormone receptors or HER2 overexpression. Prior work has identified that mRNA 
for folate receptor α (FRα) is significantly higher in TNBC than in other breast 
cancer subtypes [154]. Novel compounds that activate AMPKα or reduce Akt 
isoform expression could be conjugated to folate, which should preferentially 
target TNBC cells that have high expression of FRα. Benign cells that have lower 
levels of FRα should largely be spared. The drug conjugate will be transported 
into the cancer cells through receptor-mediated endocytosis [155]. Folate-
targeted therapy is under investigation with vintafolide, which is composed of 
desacetylvinblastine monohydrazide (DAVLBH) conjugated to folate [155]. 
DAVLBH is a derivative of vinblastine and is released into tumor cells where it 
suppresses cell division and promotes cell death [155]. Vinblastine has been 
analyzed in phase II and III clinical trials in ovarian and lung cancers [155]. If 
agents that activate AMPKα or reduce Akt isoform expression can be conjugated 
to folate, then it is likely that they can be selectively targeted to TNBC cells. 
 
5.8 Final Thoughts 
 
TNBC patients who have RD after administration of NAC desperately 
need novel therapeutic interventions. In particular, such strategies could be 
targeted toward TNBC patients with stage II or III disease that is refractory to 
NAC. AMPK and Akt are important regulators of cellular metabolism that can also 
affect cell cycle progression and proliferation. As a result, these pathways are 
prime targets to enhance current therapeutic regimens for TNBC patients. AMPK 
activators can reduce proliferation of cancer cells. FND-4b is a novel compound 
that can activate AMPK, suppress growth, and induce apoptosis at low 
micromolar concentrations in TNBC cells. Future work could analyze whether 
AMPK activators can enhance adjuvant or neoadjuvant chemotherapy. Targeting 
Akt signaling may also enhance TNBC therapy and improve patient survival. 
Silencing Akt1 sensitized TNBC cells to radiation-induced apoptosis, and 
pharmacological reduction of Akt1 expression with MK-2206 48h after 
radiotherapy synergistically promoted apoptosis. These findings indicate that 
there may be clinical benefit in reducing Akt1 expression during radiation 
treatment. In addition, knockdown of Akt1 or Akt2 dramatically decreased TNBC 
lung colonization in a kinase-independent manner. Suppressing TNBC 
metastasis may prevent distant recurrence while treatment strategies are 
adjusted for patients with RD. Clinical trials could further analyze the effects of 
AMPK activation and Akt isoform suppression in TNBC patients with resistant 
disease. Taken together, these studies identify promising approaches that may 
improve therapeutic response among TNBC patients whose tumors are 
refractory to NAC—especially those with resistant stage II or III TNBC. 
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